<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome - Young, MK - 2015 | Cochrane Library</title> <meta content="Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome - Young, MK - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010586.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome - Young, MK - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010586.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010586.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome" name="citation_title"/> <meta content="Megan K Young" name="citation_author"/> <meta content="Griffith University" name="citation_author_institution"/> <meta content="megan.young@griffith.edu.au" name="citation_author_email"/> <meta content="Allan W Cripps" name="citation_author"/> <meta content="Griffith University" name="citation_author_institution"/> <meta content="Graeme R Nimmo" name="citation_author"/> <meta content="Pathology Queensland" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD010586.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010586.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010586.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010586.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Infusions, Intravenous; Injections, Intramuscular; Post‐Exposure Prophylaxis [*methods]; Prospective Studies; Randomized Controlled Trials as Topic; Rubella [*prevention &amp; control]; Rubella Syndrome, Congenital [*prevention &amp; control]; Sodium Chloride [administration &amp; dosage]; gamma‐Globulins [*administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010586.pub2&amp;doi=10.1002/14651858.CD010586.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010586\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010586\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","ta","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010586.pub2",title:"Post\\u2010exposure passive immunisation for preventing rubella and congenital rubella syndrome",firstPublishedDate:"Sep 9, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010586.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010586.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010586.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010586.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010586.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010586.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010586.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010586.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010586.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010586.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2018 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010586.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/appendices#CD010586-sec-0086"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/table_n/CD010586StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/table_n/CD010586StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Post‐exposure passive immunisation for preventing rubella and congenital rubella syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#CD010586-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Megan K Young</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#CD010586-cr-0003">Allan W Cripps</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#CD010586-cr-0004">Graeme R Nimmo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information#CD010586-cr-0005">Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information/en#CD010586-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010586.pub2">https://doi.org/10.1002/14651858.CD010586.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010586-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010586-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010586-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010586-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010586-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010586-abs-0001" lang="en"> <section id="CD010586-sec-0001"> <h3 class="title" id="CD010586-sec-0001">Background</h3> <p>Control of rubella is desired because infection in early pregnancy can result in miscarriage, foetal death or congenital abnormality. Primary studies examining the effectiveness of immunoglobulins for post‐exposure prophylaxis of rubella have small sample sizes and varying results. National public health recommendations suggest a degree of effectiveness. </p> </section> <section id="CD010586-sec-0002"> <h3 class="title" id="CD010586-sec-0002">Objectives</h3> <p>To assess the effectiveness of intramuscular injection or intravenous infusion of polyclonal immunoglobulins of human sera or plasma origin for preventing rubella and congenital rubella syndrome when administered to exposed susceptible people before the onset of disease. </p> </section> <section id="CD010586-sec-0003"> <h3 class="title" id="CD010586-sec-0003">Search methods</h3> <p>We searched CENTRAL (2014, Issue 7), MEDLINE (1946 to August week 2, 2014), EMBASE (1974 to August 2014), CINAHL (1981 to August 2014), LILACS (1982 to August 2014) and Web of Science (1955 to August 2014). We searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry on 16 October 2014. We searched the reference lists of relevant retrieved reviews and studies and identified national public health guidelines. </p> </section> <section id="CD010586-sec-0004"> <h3 class="title" id="CD010586-sec-0004">Selection criteria</h3> <p>For the outcome 'preventing cases of rubella', we included randomised controlled trials (RCTs) and quasi‐RCTs. We found several studies addressing this outcome where the design was a controlled clinical trial (CCT) (with exposure to rubella virus controlled by the investigators) but the method of allocation of participants to groups was not reported. We found an alternative report of one of these studies that indicated participants were assigned to groups randomly. We therefore included such studies as meeting criteria for RCTs or quasi‐RCTs and undertook sensitivity analyses. For the outcomes, 'congenital rubella infection' and 'congenital rubella syndrome', we included RCTs, quasi‐RCTs and prospective controlled (cohort) studies. Participants were necessarily susceptible and exposed to rubella. Polyclonal immunoglobulins derived from human sera or plasma must have been administered intramuscularly or intravenously as the only intervention in at least one group. </p> </section> <section id="CD010586-sec-0005"> <h3 class="title" id="CD010586-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by The Cochrane Collaboration.</p> </section> <section id="CD010586-sec-0006"> <h3 class="title" id="CD010586-sec-0006">Main results</h3> <p>We included 12 studies (430 participants) in the review: seven RCTs and five CCTs where it was not clear whether participants were randomly allocated to groups. We did not include any unpublished studies. Participants included children and adults of both sexes. Only one study included pregnant women. All studies were conducted in high‐income countries. </p> <p>The quality of the 11 studies in the initial meta‐analysis was moderate, although we classified no study as having a low risk of bias on all criteria. </p> <p>We included 11 studies in the initial meta‐analysis of gamma‐globulin (concentrated polyclonal immunoglobulins) versus control (saline or no treatment) for rubella cases. The result favoured the intervention group (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.45 to 0.83) but was heterogenous (Chi² test = 36.59, df = 10 (P value &lt; 0.0001); I² statistic = 73%). Heterogeneity was explained by subgrouping studies according to the estimated volume of gamma‐globulin administered per pound of bodyweight and then removing those studies where the intervention was administered more than five days after participant exposure to rubella (post hoc analysis). The test of subgroup differences demonstrated heterogeneity between subgroups according to our protocol definition (P value &lt; 0.1; I² statistic &gt; 60%) and there appeared to be greater effectiveness of the intervention when a greater volume of gamma‐globulin was administered ('0.027 to 0.037 ml/lb' RR 1.60 (95% CI 0.57 to 4.52); '0.1 to 0.15 ml/lb' RR 0.53 (95% CI 0.29 to 0.99); '0.2 to 0.5 ml/lb' RR 0.20 (95% CI 0.04 to 1.00)). </p> <p>None of the studies reported the outcome 'congenital rubella infection'. One included study reported on congenital rubella syndrome, with no cases among participants who were fewer than nine weeks pregnant at enrolment and who were randomised to one of two gamma‐globulin groups ('high' or 'low' rubella titre). However, the study did not report how congenital rubella syndrome was measured and did not report the length of follow‐up according to intervention group. This study did not include a non‐treatment group. </p> <p>No included study measured adverse events.</p> </section> <section id="CD010586-sec-0007"> <h3 class="title" id="CD010586-sec-0007">Authors' conclusions</h3> <p>Compared to no treatment, polyclonal immunoglobulins seem to be of benefit for preventing rubella. The available evidence suggests that this intervention may be of benefit up to five days after exposure, and that effectiveness is dependent on dose. Considering the attack rate for rubella cases in the control group of the highest volume gamma‐globulin subgroup (333 per 1000), the absolute risk reduction (calculated from the RR) for this volume of gamma‐globulin was 266 (95% CI 0 to 320) and the number needed to treat to benefit is four (95% CI 3 to incalculable). </p> <p>The included studies did not measure rubella‐specific antibodies in the immunoglobulin products used in a standard way and thus estimation of the dose of rubella‐specific antibodies in international units administered was not possible. As the concentration of rubella‐specific antibodies in today's polyclonal immunoglobulin products may vary from those products used in the studies in the review, the volume required per pound of bodyweight to produce similar results may also vary. </p> <p>There is insufficient evidence to make direct conclusions about the effectiveness of polyclonal immunoglobulins for preventing congenital rubella syndrome. This is an area requiring further research. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010586-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010586-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010586-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010586-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010586-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010586-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ta#CD010586-abs-0007">தமிழ்</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010586-abs-0004" lang="en"> <h3>Passive immunisation (giving antibodies) for preventing rubella (German measles) after contact with it </h3> <p><b>Background and review question</b> <br/> People who have had rubella (German measles), or rubella vaccine, have antibodies against the virus in their blood. These antibodies protect them from getting rubella should they come into contact with it again. These antibodies can be extracted from blood donated by these people. </p> <p>If people without antibodies come into contact with someone who is contagious with rubella, they can contract it. Rubella can be serious. The baby of a woman who is infected with rubella, especially early in pregnancy, may be born with a range of birth defects including heart, eye and hearing problems. One way of preventing rubella in people who come into contact with a contagious person is to inject them with antibodies that have been extracted from blood donations. This was done in the 1950s and 1960s and is still recommended for rubella control in some circumstances in some countries. Whether this is effective is unclear. We sought to answer this question. </p> <p><b>Study characteristics</b> <br/> The evidence is current to August 2014. We included 12 studies (430 participants). People of all ages were included in the studies, which were conducted in high‐income countries. </p> <p><b>Key results and quality of the evidence</b> <br/> Eleven studies (389 participants) compared injecting antibodies into the muscle or vein of participants to injecting salt water or giving no treatment. The study participants did not have their own antibodies. They had been in contact with rubella between one and 28 days prior to receiving the antibodies. The antibodies seemed to be effective at preventing participants from catching rubella, with those receiving antibodies 39% less likely to develop rubella than those not given antibodies. In an analysis of the seven studies (89 participants) where participants had been in contact with rubella only up to five days earlier, people given the highest doses used in the studies were 80% less likely to develop rubella than those not given antibodies. The studies assessing the prevention of rubella were of moderate quality because of some methodological issues and the fairly small number of participants. It is important to consider that the amount of rubella antibodies in today's blood donations may differ from those used in the studies. Therefore, doses given today may need to vary from those of the studies in order to obtain the same effect. </p> <p>Only one study included pregnant women. All of the women were given one of two different doses of antibodies. They did not measure whether the babies born to the women were infected with rubella, but did consider whether birth defects that may be related to rubella were present. Key details about the study methods were missing and unobtainable, so the quality of this study was unclear. None of the babies born to these women were identified as having birth defects related to rubella. However, we cannot draw direct conclusions from this single study about the effectiveness of injecting antibodies after contact with rubella for preventing rubella‐related birth defects in pregnant women. This is an area that needs further research. </p> <p>The included studies did not report adverse events. Future studies should report this outcome. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010586-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010586-sec-0081"></div> <h3 class="title" id="CD010586-sec-0082">Implications for practice</h3> <section id="CD010586-sec-0082"> <p>Compared to no treatment, passive immunisation seems to be of benefit for preventing rubella. The available evidence suggests that this intervention may be of benefit up to five days after exposure, and that effectiveness is dependent on sufficient dose. Considering the attack rate for rubella cases in the control group of the highest volume gamma‐globulin subgroup (333 per 1000), the absolute risk reduction (calculated from the risk ratio (RR) (<a href="./references#CD010586-bbs2-0164" title="HigginsJ , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane‐handbook.org. ">Higgins 2011</a>)) for this volume of gamma‐globulin was 266 (95% CI 0 to 320) and the number needed to treat to benefit (NNTB) is four (95% confidence interval (CI) 3 to incalculable). </p> <p>The included studies did not measure rubella‐specific antibodies in the gamma‐globulin products used in a standard way and thus estimation of the dose of rubella‐specific antibodies in international units administered was not possible. As the concentration of rubella‐specific antibodies in today's gamma‐globulin products may vary from those products used in the studies in the review (<a href="./references#CD010586-bbs2-0143" title="BarlinnR , VainioK , SamdalHH , NordboSA , NoklebyH , DudmanSG . Susceptibility to cytomegalovirus, parvovirus B19 and age‐dependent differences in levels of rubella antibodies among pregnant women. Journal of Medical Virology2014;86:820‐6. ">Barlinn 2014</a>; <a href="./references#CD010586-bbs2-0192" title="Vauloup‐FallousC , Grangeot‐KerosL . Humoral immune response after primary rubella virus infection and after vaccination. Clinical and Vaccine Immunology2007;14(5):644‐7. ">Vauloup‐Fellous 2007</a>), the volume required per pound of bodyweight to produce similar beneficial results may also vary. </p> <p>There is insufficient evidence to make direct conclusions about the effectiveness of post‐exposure passive immunisation for preventing congenital rubella syndrome. </p> <p>The benefits of an intervention should always be weighed against the risks. While the studies included in this review did not measure or report adverse events, potential adverse events related to passive immunisation can be found in the published literature and product information (for example <a href="./references#CD010586-bbs2-0140" title="AshwellM . Normal immunoglobulin (human): indications and safety. New South Wales Public Health Bulletin1997;8(10):85. ">Ashwell 1997</a>, <a href="./references#CD010586-bbs2-0152" title="CSLLimited . Product information: normal immunoglobulin‐VF Australia. Available from: http://www.csl.com.au/docs/91/387/Normal%20Immunoglobulin%20AU%20PI%208.00.pdf 2014 (accessed 20 February 2015). ">CSL 2014</a>, <a href="./references#CD010586-bbs2-0156" title="Electronic MedicinesCompendium . Subgam, Human normal immunoglobulin solution. Available at: https://www.medicines.org.uk/emc/medicine/14826 2014 (accessed 30 January 2015). ">EMC 2014</a>, <a href="./references#CD010586-bbs2-0158" title="European Agency for the Evaluation of Medicinal Products. Core SPC for human normal immunoglobulin for subcutaneous and intramuscular use. 2002. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003610.pdf 2002 (accessed 30 January 2015). ">EMEA 2002</a> and <a href="./references#CD010586-bbs2-0183" title="SawyerLA . Antibodies for the prevention and treatment of viral diseases. Antiviral Research2000;47:57‐77. ">Sawyer 2000</a>). </p> </section> <h3 class="title" id="CD010586-sec-0083">Implications for research</h3> <section id="CD010586-sec-0083"> <p>Preventing rubella infection among those susceptible after they have been exposed is most important for the subpopulation of exposed susceptible pregnant women. Given the paucity of evidence in this population, and because it would be unethical to design a study with an investigator‐controlled placebo comparison group, observational studies comparing the infection status and pregnancy outcomes of exposed susceptible pregnant women with and without post‐exposure passive immunisation would be of benefit. Studies should include careful recording of any potential adverse events. Given that dose appears to be important to the magnitude of effectiveness, studies should also include measurement of the concentration of rubella‐specific antibodies in the blood product/s used. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010586-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010586-sec-0022"></div> <div class="table" id="CD010586-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> susceptible people exposed to rubella<br/> <b>Settings:</b> community, different residential institutions, universities and medical settings<br/> <b>Intervention:</b> gamma‐globulin<br/> <b>Comparison:</b> saline or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (saline or no treatment)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Gamma‐globulin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rubella cases</b> <br/> Initial meta‐analysis ‐ clinical diagnosis or serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 3 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.45 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> <br/> (123 to 226) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (257 to 474) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.027 to 0.037 ml/lb<sup>11</sup> </b> <br/> Clinical diagnosis by 2 physicians<br/> Follow‐up: 21+ days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.6</b> <br/> (0.57 to 4.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>533 per 1000</b> <br/> (190 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>914 per 1000</b> <br/> (325 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.1 to 0.15 ml/lb<sup>11</sup> </b> <br/> Serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 6 to 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.53</b> <br/> (0.29 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>37<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>765 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> <br/> (222 to 757) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b> <br/> (166 to 565) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.2 to 0.5 ml/lb<sup>11</sup> </b> <br/> Serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 3 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.2</b> <br/> (0.04 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>28<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (13 to 333) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> <br/> (23 to 571) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of congenital rubella infection</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured the outcome congenital rubella infection</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of congenital rubella syndrome</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies of gamma‐globulin versus control measured the outcome congenital rubella syndrome<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies included in the initial meta‐analysis. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias. Most information was from studies at low and unclear risk of bias. Two studies were at high risk of detection bias only. Three studies were at high risk of selective reporting only, and this was unlikely to affect their results.<br/> <sup>2</sup>Downgraded one level for inconsistency. The studies' results were statistically heterogenous.<br/> <sup>3</sup>Upgraded one level for plausible confounding would reduce the measure of effect. The plausible confounding factors we listed a priori were: dose, time between exposure and intervention, immunosuppression, age and gestation. No studies in this meta‐analysis included pregnant women or identified immunosuppressed individuals. Subgroup analysis by age showed no difference between the subgroups. This analysis includes studies where the intervention was administered longer than five days after exposure and includes studies that administered lower volumes of immunoglobulin per unit weight than others. Both of these factors would reduce the measure of effect.<br/> <sup>4</sup>Downgraded one level for risk of bias. The sole study in this subgroup was at high risk of detection bias as the outcome was assessed subjectively and there was no reported blinding of outcome assessors.<br/> <sup>5</sup>Downgraded two levels for imprecision. The sole study in this subgroup had a small sample size and the resulting confidence interval is wide.<br/> <sup>6</sup>Upgraded one level for apparent dose response effect. While there is overlap in the confidence intervals, there appeared to be heterogeneity across estimated dose subgroups (P value = 0.07; I² = 62.4%) and the estimates of effect seemed to indicate greater effectiveness with greater estimated dose.<br/> <sup>7</sup>Downgraded one level for imprecision. Each trial in this subgroup was of small sample size and the overall sample size for the subgroup is small. However, the confidence interval does not include one.<br/> <sup>8</sup>Downgraded one level for risk of bias. Two of the three studies in this subgroup had a high risk of selective reporting bias.<br/> <sup>9</sup>Downgraded two levels for imprecision. The trials in this subgroup were small, the overall sample size of the subgroup was small and the confidence interval of the pooled estimate of effect extended to 1.00.<br/> <sup>10</sup>Upgraded one level for large effect estimate. The pooled estimate of effect for this subgroup was 0.2.<br/> <sup>11</sup>This subgroup analysis excluded studies where the intervention was provided more than five days after exposure.<br/> <sup>12</sup>One study included in the review compared a 'high' titre gamma‐globulin with a 'low' titre gamma‐globulin control group. This study did not identify any cases of congenital rubella syndrome among any of the infants born to participants although the means of assessment was not reported and the length of follow‐up was not given by study group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010586-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010586-sec-0023"></div> <p>Global rubella control has progressed since the introduction of rubella vaccine (<a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>; <a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). However, country‐specific control varies greatly, with some countries citing evidence of rubella elimination (<a href="./references#CD010586-bbs2-0144" title="BestJ . Rubella. Seminars in Fetal &amp; Neonatal Medicine2007;12:182‐92. ">Best 2007</a>; <a href="./references#CD010586-bbs2-0180" title="ReefS , ReddS , AbernathyE , KuttyP , IcenogleJ . Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States. Journal of Infectious Diseases2011;204(Suppl 2):593‐7. ">Reef 2011</a>), while the burden of disease is unknown and rubella vaccination is still unavailable in others (<a href="./references#CD010586-bbs2-0160" title="GoodsonJ , MasreshaB , DossehA , ByabamazimaC , NshimirimanaD , CochiS , et al. Rubella epidemiology in Africa in the prevaccine era, 2002‐2009. Journal of Infectious Diseases2011;204(Suppl 1):215‐25. ">Goodson 2011</a>). Many countries report large numbers of cases and outbreaks of rubella (<a href="./references#CD010586-bbs2-0170" title="MuscatM , ZimmermanL , BacciS , BangH , GlismannS , MolbakK , et al. Toward rubella elimination in Europe: an epidemiological assessment. Vaccine2012;30:1999‐2007. ">Muscat 2012</a>; <a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>; <a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). Though vaccination is available in these countries, rates are not sufficiently high to achieve adequate rubella control (<a href="./references#CD010586-bbs2-0170" title="MuscatM , ZimmermanL , BacciS , BangH , GlismannS , MolbakK , et al. Toward rubella elimination in Europe: an epidemiological assessment. Vaccine2012;30:1999‐2007. ">Muscat 2012</a>; <a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>). In 2009, more than 120,000 cases of rubella and 165 cases of congenital rubella syndrome (CRS) (see <a href="#CD010586-sec-0024">Description of the condition</a>) were reported to the World Health Organization (WHO) by member states (<a href="./references#CD010586-bbs2-0188" title="StrebelP , DabbaghA , Gacic‐DoboM , ReefSE , CochiS . Progress toward control of rubella and prevention of congenital rubella syndrome ‐ worldwide, 2009. MMRW. Morbidity and Mortality Weekly Report2010;59(40):1307‐10. ">Strebel 2010</a>). However, these figures are believed to be a gross underestimate of the global burden of disease, with modelling predicting 110,000 cases of CRS in low‐income countries during the non‐epidemic year of 1996 (<a href="./references#CD010586-bbs2-0153" title="CuttsFT , VynnyckyE . Modelling the incidence of congenital rubella syndrome in developing countries. International Journal of Epidemiology1999;28:1176‐84. ">Cutts 1999</a>). Under‐reporting of rubella and CRS is thought to be a particular problem in the WHO's African, South‐East Asia and Eastern Mediterranean Regions (<a href="./references#CD010586-bbs2-0188" title="StrebelP , DabbaghA , Gacic‐DoboM , ReefSE , CochiS . Progress toward control of rubella and prevention of congenital rubella syndrome ‐ worldwide, 2009. MMRW. Morbidity and Mortality Weekly Report2010;59(40):1307‐10. ">Strebel 2010</a>). Even in countries with low incidences of rubella, groups with low vaccination coverage persist and cases of CRS are still reported (<a href="./references#CD010586-bbs2-0170" title="MuscatM , ZimmermanL , BacciS , BangH , GlismannS , MolbakK , et al. Toward rubella elimination in Europe: an epidemiological assessment. Vaccine2012;30:1999‐2007. ">Muscat 2012</a>; <a href="./references#CD010586-bbs2-0187" title="SongN , GaoZ , WoodJ , HuestonL , GilbertC , MacIntyreR , et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine2012;30:4073‐8. ">Song 2012</a>). </p> <p>The proportion of women of child bearing age who are not immune to rubella also varies around the world. Some countries, such as Sweden, the Czech Republic and Australia, have recorded figures of less than 5% (between 1996 and 2004) (<a href="./references#CD010586-bbs2-0171" title="NardoneA , TischerA , AndrewsN , BackhouseJ , TheetenH , GatchevaN , et al. Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets. Bulletin of the World Health Organization2008;86:118‐25. ">Nardone 2008</a>), while others have much higher proportions; for example, Bangladesh (16% in 2004 to 2005) (<a href="./references#CD010586-bbs2-0172" title="NessaA , IslamMN , TabassumS , MunshiSU , AhmedM , KarimR . Seroprevalence of rubella among urban and rural Bangladeshi women emphasises the need for rubella vaccination of pre‐pubertal girls. Indian Journal of Medical Microbiology2008;26(1):94‐5. ">Nessa 2008</a>), Singapore (16% in 2004) (<a href="./references#CD010586-bbs2-0139" title="AngLW , ChuaLT , JamesL , GohKT . Epidemiological surveillance and control of rubella in Singapore, 1991‐2007. Annals of the Academy of Medicine, Singapore2010;39(2):95‐101. ">Ang 2010</a>), Morocco (17% in 2000) (<a href="./references#CD010586-bbs2-0149" title="CaidiH , BloomS , AzilmaatM , BenjouadA , ReefS , ElAouadR . Rubella seroprevalence among women aged 15‐39 years in Morocco. Eastern Mediterranean Health Journal 15;3:526‐31. ">Caidi 2009</a>), India (12% to 23% between 2000 to 2008) (<a href="./references#CD010586-bbs2-0155" title="DewanP , GuptaP . Burden of congenital rubella syndrome (CRS) in India: a systematic review. Indian Pediatrics2012;49:377‐99. ">Dewan 2012</a>) and Turkey (45% in one city in 2005) (<a href="./references#CD010586-bbs2-0182" title="SasmazT , Oner KurtA , OzturkC , BugdayciR , OnerS . Rubella seroprevalence in women in the reproductive period, Mersin, Turkey. Vaccine2007;25:912‐7. ">Sasmaz 2007</a>). </p> <p>The cost of treating a child with CRS has been estimated in several countries. In Panama in 1989, the annual treatment cost was estimated as USD 2291, while in Jamaica in 1997, it was estimated as USD 13,482 (<a href="./references#CD010586-bbs2-0165" title="HinmanAR , IronsB , LewisM , KandolaK . Economic analyses of rubella and rubella vaccines: a global review. Bulletin of the World Health Organization2002;80:264‐70. ">Hinman 2002</a>). The lifetime cost of treating a child with CRS was estimated to be USD 50,000 and USD 63,990 in Barbados and Guyana respectively in 1997 and USD 300,000 in the United States of America in the 1980s (<a href="./references#CD010586-bbs2-0165" title="HinmanAR , IronsB , LewisM , KandolaK . Economic analyses of rubella and rubella vaccines: a global review. Bulletin of the World Health Organization2002;80:264‐70. ">Hinman 2002</a>). </p> <p>While vaccination is the cornerstone for the prevention of CRS at the population level, there is little in the way of prevention to offer susceptible pregnant woman exposed to the rubella virus. Before rubella vaccine became available, passive immunisation was investigated as a means of preventing rubella infection, with mixed results (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). Countries with low incidences of rubella still recommend the use of passive immunisation for the individual exposed and susceptible pregnant woman in certain circumstances. </p> <p>The national recommendations in the United States (US), the United Kingdom (UK) and New Zealand (NZ) suggest offering passive immunisation (a single injection of human immunoglobulin (IG)) to exposed pregnant women for whom termination of pregnancy is not acceptable should rubella infection occur (<a href="./references#CD010586-bbs2-0150" title="Centers for Disease Control and Prevention. Measles, mumps, and rubella ‐ vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report1998;47(RR8):1‐57. ">CDC 1998</a>; <a href="./references#CD010586-bbs2-0151" title="Centers for Disease Control and Prevention. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR ‐ Morbidity and Mortality Weekly Report2001;50(RR12):1‐23. ">CDC 2001</a>; <a href="./references#CD010586-bbs2-0166" title="Immunisation Department, Health Protection Agency. Immunoglobulin Handbook. United Kingdom: Health Protection Agency, 2009. ">IDHPA 2009</a>; <a href="./references#CD010586-bbs2-0174" title="New Zealand Ministry of Health. Immunisation Handbook. Wellington: New Zealand Ministry of Health, 2014. ">NZMoH 2014</a>; <a href="./references#CD010586-bbs2-0176" title='Public Health England. Chapter 28: Rubella ‐ last updated 4 April 2013. Immunisation Against Infectious Disease ‐ "The Green Book". London: United Kingdom Department of Health, 2013. '>PHE 2013</a>). Australian recommendations are similar but do not include consideration of termination of pregnancy (<a href="./references#CD010586-bbs2-0142" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government, 2013. ">ATAGI 2013</a>). The rationales for these recommendations differ. For example, the UK Immunoglobulin Handbook suggests IG "does not prevent infection in non‐immune contacts but may reduce the likelihood of clinical symptoms, which may possibly reduce the risk to the foetus" (<a href="./references#CD010586-bbs2-0166" title="Immunisation Department, Health Protection Agency. Immunoglobulin Handbook. United Kingdom: Health Protection Agency, 2009. ">IDHPA 2009</a>); the NZ Immunisation Handbook states "Although IG has been shown to reduce clinically apparent infection in the mother, there is no guarantee that foetal infection will be prevented" (<a href="./references#CD010586-bbs2-0174" title="New Zealand Ministry of Health. Immunisation Handbook. Wellington: New Zealand Ministry of Health, 2014. ">NZMoH 2014</a> p452); and the Australian Immunisation Handbook states that IG may prolong the incubation period, which may reduce the risk to the foetus (<a href="./references#CD010586-bbs2-0142" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government, 2013. ">ATAGI 2013</a>). The recommended doses of IG also differ. </p> <p>Despite the differences, these countries' national recommendations suggest some degree of effectiveness of passive immunisation for preventing rubella. However, they do not indicate the magnitude of the effect, nor (where applicable) adequately explain why a woman's thoughts about termination should influence the practice of passive immunisation in this situation. </p> <section id="CD010586-sec-0024"> <h3 class="title" id="CD010586-sec-0024">Description of the condition</h3> <p>Rubella is a single‐stranded ribonucleic acid (RNA) virus that is transmitted by respiratory droplets or direct contact with the respiratory secretions of an infectious person (<a href="./references#CD010586-bbs2-0163" title="HeymannD (editor) . Control of Communicable Diseases Manual. 19th Edition. Washington: American Public Health Association, 2008. ">Heymann 2008</a>). Someone with rubella is infectious from up to seven days before and until 14 days after the onset of rash, though the time of greatest infectivity is at rash onset (<a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>; <a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). A susceptible person exposed to rubella will develop the disease between 12 and 23 days after exposure (<a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). </p> <p>Rubella is typically a mild, self limiting disease in susceptible children and adults (<a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). Up to 50% of rubella virus infections are asymptomatic (<a href="./references#CD010586-bbs2-0163" title="HeymannD (editor) . Control of Communicable Diseases Manual. 19th Edition. Washington: American Public Health Association, 2008. ">Heymann 2008</a>; <a href="./references#CD010586-bbs2-0175" title="PattisonJR , DaneDS . The routine serological investigation of cases and contacts of rubella. Journal of Hygiene1975;75(1):91‐8. ">Pattison 1975</a>). When present, symptoms include fever, headache, a generalised red blotchy rash, tender enlarged lymph nodes, joint pain and mild conjunctivitis (<a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>). Occasionally (one in 6000 cases), rubella infection may be complicated by encephalitis (<a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). </p> <p>The diagnosis of rubella is typically confirmed by measuring the increase in a particular type of rubella‐specific antibody (rubella‐specific IgG) in blood or by growing the virus from, or detecting the virus in, respiratory secretions, urine or blood (<a href="./references#CD010586-bbs2-0177" title="Public Health Laboratory Network. Laboratory case definitions: rubella (postnatal and congenital) laboratory case definition. Australian Government Department of Health and Ageing. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda‐phlncd‐rubella 2010 (accessed 7 January 2012). ">PHLN 2010</a>). The presence of another type of rubella‐specific antibody (rubella‐specific IgM) is also indicative of disease (<a href="./references#CD010586-bbs2-0151" title="Centers for Disease Control and Prevention. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR ‐ Morbidity and Mortality Weekly Report2001;50(RR12):1‐23. ">CDC 2001</a>). </p> <p>Control of rubella is desired because infection during the early part of pregnancy can result in miscarriage, foetal death or congenital abnormality (<a href="./references#CD010586-bbs2-0191" title="UsonisV , AncaI , AndreF , ChlibekR , CizmanM , IvaskevicieneI , et al. Rubella revisited: where are we on the road to disease elimination in Central Europe?. Vaccine2011;29:9141‐7. ">Usonis 2011</a>). An infant born with any of the common congenital defects resulting from foetal rubella infection is said to have CRS. This includes cataracts, congenital heart disease, hearing impairment and microcephaly (<a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>). Estimates of the risk of CRS after rubella infection during pregnancy vary considerably but it is agreed that the risk decreases as the pregnancy progresses (<a href="./references#CD010586-bbs2-0144" title="BestJ . Rubella. Seminars in Fetal &amp; Neonatal Medicine2007;12:182‐92. ">Best 2007</a>; <a href="./references#CD010586-bbs2-0154" title="DeSantisM , CavaliereAF , StrafaceG , CarusoA . Rubella infection in pregnancy. Reproductive Toxicology2006;21:390‐8. ">De Santis 2006</a>). De Santis et al have summarised a large number of studies, indicating that the risk of CRS when rubella infection occurs in the first trimester (12 weeks) of pregnancy is between 38% and 100%, when infection occurs in the second trimester is between 4% and 60% and when infection occurs in the third trimester is between 0% and 18% (<a href="./references#CD010586-bbs2-0154" title="DeSantisM , CavaliereAF , StrafaceG , CarusoA . Rubella infection in pregnancy. Reproductive Toxicology2006;21:390‐8. ">De Santis 2006</a>). The types of defects likely to manifest also vary according to the stage of pregnancy when infection occurs (<a href="./references#CD010586-bbs2-0023" title="BanatvalaJE , BrownDWG . Rubella. Lancet2004;363(9415):1127‐37. ">Banatvala 2004</a>). Multiple defects are more likely to occur when infection is early in the pregnancy (<a href="./references#CD010586-bbs2-0144" title="BestJ . Rubella. Seminars in Fetal &amp; Neonatal Medicine2007;12:182‐92. ">Best 2007</a>). Hearing impairment is typically the only defect resulting from infection after the 16th week of pregnancy (<a href="./references#CD010586-bbs2-0195" title="World Health Organization. Rubella vaccines: WHO position paper. Weekly Epidemiological Record2011;86(29):301‐16. ">WHO 2011</a>), while impairment of foetal growth may continue to occur as a result of infection in the third trimester (<a href="./references#CD010586-bbs2-0154" title="DeSantisM , CavaliereAF , StrafaceG , CarusoA . Rubella infection in pregnancy. Reproductive Toxicology2006;21:390‐8. ">De Santis 2006</a>). </p> <p>The diagnosis of congenital rubella syndrome is confirmed in babies with suggestive congenital malformations by detecting rubella‐specific IgM in their blood, measuring the increase in rubella‐specific IgG in the first year of life, or by growing the virus from, or detecting the virus in, respiratory secretions or urine (<a href="./references#CD010586-bbs2-0177" title="Public Health Laboratory Network. Laboratory case definitions: rubella (postnatal and congenital) laboratory case definition. Australian Government Department of Health and Ageing. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda‐phlncd‐rubella 2010 (accessed 7 January 2012). ">PHLN 2010</a>). </p> </section> <section id="CD010586-sec-0025"> <h3 class="title" id="CD010586-sec-0025">Description of the intervention</h3> <p>In the early days of passive immunisation, a number of formulations of immunoglobulins were used. These included the serum of someone who was convalescing from the disease; the serum of an animal that had been actively immunised against the disease; or concentrated gamma‐globulins (one class of immunoglobulins) derived from either pooled extracts from human placentas, pooled blood from human placentas or pooled human blood (<a href="./references#CD010586-bbs2-0169" title="McDonaghT . Passive immunization with gamma globulin. Journal of Occupational Medicine1966;8(11):567‐72. ">McDonagh 1966</a>). Modern passive immunisation has changed little from this last technique. It involves administration of concentrated immunoglobulins, mostly gamma‐globulins, derived from at least 1000 adult blood donations (<a href="./references#CD010586-bbs2-0194" title="World Health Organization. Annex 2: Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. Geneva: World Health Organization, 1994. ">WHO 1994</a>). Different products are available for intramuscular and intravenous administration (<a href="./references#CD010586-bbs2-0147" title="BurnoufT . Modern plasma fractionation. Transfusion Medicine Reviews2007;21(2):101‐17. ">Burnouf 2007</a>). With respect to rubella, the product recommended is usually human polyclonal immunoglobulins for intramuscular injection (IG). The concentration of rubella‐specific immunoglobulins (antibodies) in polyclonal immunoglobulin products may vary depending on manufacturing processes and the average level of rubella‐specific antibodies in the donated blood (<a href="./references#CD010586-bbs2-0186" title="SimonHU , SpathPJ . IVIG ‐ mechanism of action. Allergy2003;58:543‐52. ">Simon 2003</a>). </p> </section> <section id="CD010586-sec-0026"> <h3 class="title" id="CD010586-sec-0026">How the intervention might work</h3> <p>Whether injected or infused, the administered immunoglobulins distribute throughout the recipient's body into the spaces between cells (<a href="./references#CD010586-bbs2-0145" title="BirdsallHH . Antibodies. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone, 2009. ">Birdsall 2009</a>). The mechanism by which the recipient might be protected from disease involves interaction between the immunoglobulins (antibodies), the invading rubella virus particles and the cells and molecules of the recipient's immune system (<a href="./references#CD010586-bbs2-0179" title="ReadingS , DimmockN . Neutralization of animal virus infectivity by antibody. Archives of Virology2007;152:1047‐59. ">Reading 2007</a>). The exact mechanisms by which viral infectivity is mitigated by antibodies within the body are not comprehensively understood but vary according to the structure and functionality of the particular antibodies as they encounter the particular virus particles (<a href="./references#CD010586-bbs2-0179" title="ReadingS , DimmockN . Neutralization of animal virus infectivity by antibody. Archives of Virology2007;152:1047‐59. ">Reading 2007</a>). For viruses in general, several mechanisms of action are thought to occur. Firstly and most importantly, antibodies bind to the invading particles, directly preventing their entry into cells; a process called neutralisation (<a href="./references#CD010586-bbs2-0145" title="BirdsallHH . Antibodies. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone, 2009. ">Birdsall 2009</a>; <a href="./references#CD010586-bbs2-0148" title="BurtonD . Antibodies, viruses and vaccines. Nature Reviews Immunology2002;2(9):706‐13. ">Burton 2002</a>). Secondly, antibodies may block cell surface receptors, preventing the virus from entering the cell (<a href="./references#CD010586-bbs2-0179" title="ReadingS , DimmockN . Neutralization of animal virus infectivity by antibody. Archives of Virology2007;152:1047‐59. ">Reading 2007</a>). Thirdly, antibodies can activate other parts of the immune system resulting directly in viral destruction (<a href="./references#CD010586-bbs2-0145" title="BirdsallHH . Antibodies. In: MandellGL , BennettJE , DolinR editor(s). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone, 2009. ">Birdsall 2009</a>; <a href="./references#CD010586-bbs2-0167" title="LawM , HangartnerL . Antibodies against viruses: passive and active immunization. Current Opinion in Immunology2008;20:486‐92. ">Law 2008</a>). Finally, antibodies bind to infected cells facilitating their destruction (<a href="./references#CD010586-bbs2-0148" title="BurtonD . Antibodies, viruses and vaccines. Nature Reviews Immunology2002;2(9):706‐13. ">Burton 2002</a>; <a href="./references#CD010586-bbs2-0167" title="LawM , HangartnerL . Antibodies against viruses: passive and active immunization. Current Opinion in Immunology2008;20:486‐92. ">Law 2008</a>).   </p> </section> <section id="CD010586-sec-0027"> <h3 class="title" id="CD010586-sec-0027">Why it is important to do this review</h3> <p>No systematic review of the effectiveness of passive immunisation for the prevention of rubella currently exists and the evidence on which public health practice is based with regards to non‐immune pregnant rubella contacts is limited and somewhat contradictory. </p> <p>UK guidelines do not reference the statement that "there is no evidence that it is effective" (referring to using IG for post‐exposure prophylaxis for pregnant women) (<a href="./references#CD010586-bbs2-0166" title="Immunisation Department, Health Protection Agency. Immunoglobulin Handbook. United Kingdom: Health Protection Agency, 2009. ">IDHPA 2009</a> p359). The Australian Immunisation Handbook references the US guidelines for each of the statements about post‐exposure passive immunisation for rubella (<a href="./references#CD010586-bbs2-0142" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government, 2013. ">ATAGI 2013</a>). These Australian guidelines state that post‐exposure passive immunisation "does not prevent infection in non‐immune contacts" (<a href="./references#CD010586-bbs2-0142" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government, 2013. ">ATAGI 2013</a> p396), whereas the NZ guidelines state that "IG has been shown to reduce clinically apparent infection in the mother" but do not reference this statement (<a href="./references#CD010586-bbs2-0174" title="New Zealand Ministry of Health. Immunisation Handbook. Wellington: New Zealand Ministry of Health, 2014. ">NZMoH 2014</a> p452). The US guidelines provide two references at the end of the paragraph on post‐exposure passive immunisation against rubella (<a href="./references#CD010586-bbs2-0150" title="Centers for Disease Control and Prevention. Measles, mumps, and rubella ‐ vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report1998;47(RR8):1‐57. ">CDC 1998</a>). One is a primary controlled study on passive immunisation under experimental conditions that indicated efficacy of high‐dose immunoglobulin within 24 hours of exposure but limited efficacy at lower doses (<a href="./references#CD010586-bbs2-0184" title="SchiffG . Titred lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969d</a>). The other is a book chapter that does not include in‐text citations (<a href="./references#CD010586-bbs2-0193" title="WaagnerD . Childhood exanthems. In: KaplanS editor(s). Current Therapy in Pediatric Infectious Diseases. 3rd Edition. Saint Louis: Mosby‐Year Book Inc, 1993:274‐8. ">Waagner 1993</a>). It states that: "Immune globulin may reduce clinical findings but does not prevent viraemia". There is no indication of the dose of IG, anti‐rubella antibody concentration or timing of administration to which this statement is referring. The statement conflicts with the study by <a href="./references#CD010586-bbs2-0184" title="SchiffG . Titred lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969d</a> (the other reference used in the US guidelines) that concluded viraemia was prevented with high‐dose IG. Waagner's book chapter goes on to indicate the author's personal preference for only using immunoglobulin for pregnant women presenting within 72 hours of exposure for whom therapeutic abortion is not an option (<a href="./references#CD010586-bbs2-0193" title="WaagnerD . Childhood exanthems. In: KaplanS editor(s). Current Therapy in Pediatric Infectious Diseases. 3rd Edition. Saint Louis: Mosby‐Year Book Inc, 1993:274‐8. ">Waagner 1993</a>). In addition to the claim that IG given post‐exposure will not prevent viraemia, the author reasons that asymptomatic infection may occur in the mother post‐IG, anti‐rubella antibody titres in IG vary and there have been infants born with CRS despite post‐exposure prophylaxis with IG. Again, each of these points is unreferenced. The author does not consider the possibility of detecting asymptomatic infection in the women post‐IG administration using serial serological testing, despite the recommendation that exposed pregnant women undergo such testing immediately post‐exposure and then at two to three and six weeks post‐exposure. </p> <p>No primary research evidence has been published in the last three decades on the use of IG or immunoglobulins generally for preventing rubella in non‐immune exposed pregnant women. However, a number of controlled studies have been identified that examine the effectiveness or efficacy of passive immunisation against rubella post‐exposure (<a href="./references#CD010586-bbs2-0025" title="BassM , DavidsonHB , FooteF , MuckenfussR , LandonJF . The efficacy of gamma globulin in the prevention of German measles. New York Medicine1949;5:21‐3. ">Bass 1949</a>; <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0094" title="MacraeAD , Reid D and the Public Health Laboratory Service. Studies on rubella in pregnancy. British Medical Journal1968;3:203‐6. ">Macrae 1968</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0110" title="Neumann‐HaefelinD , Neumann‐HaefelinC , PetersenEE , LuthardtT , HassR . Passive immunization against rubella: studies on the effectiveness of rubella‐immunoglobulin after intranasal infection with rubella vaccination virus [Passive rotelnprophylaxe. Untersuchungen zur wirksamkeit von rotelnimmunglobulin nach intranasaler infektion mit roteln‐impfvirus]. Deutsche Medizinische Wochenschrift1975;100(5):177‐81. ">Neumann‐Haefelin 1975</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0184" title="SchiffG . Titred lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969d</a>). Each of these studies includes small numbers of participants and varying conclusions are drawn about the effectiveness of the intervention. No significant adverse events are noted.  </p> <p>A systematic review of the evidence provides a firm foundation on which to review current policy and practice of passive immunisation for preventing rubella and congenital rubella syndrome. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010586-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010586-sec-0028"></div> <p>To assess the effectiveness of intramuscular injection or intravenous infusion of polyclonal immunoglobulins of human sera or plasma origin for preventing rubella and congenital rubella syndrome when administered to exposed susceptible people before the onset of disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010586-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010586-sec-0029"></div> <section id="CD010586-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010586-sec-0031"> <h4 class="title">Types of studies</h4> <p><b>To assess the effectiveness of polyclonal immunoglobulins for preventing cases of rubella:</b> </p> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that examined this outcome, irrespective of blinding, publication status, language or unit of randomisation. </p> <p><i>(To note: We found several studies addressing this outcome where the design was a controlled clinical trial (with exposure to rubella virus controlled by the investigators) but the method of allocation of participants to groups was not reported. We found an alternative report of one of these studies that indicated participants were assigned to groups randomly. We therefore included such studies as meeting the criteria for RCTs or quasi‐RCTs and undertook sensitivity analyses.)</i> </p> <p><b>To assess the effectiveness of polyclonal immunoglobulins for preventing congenital rubella infection and congenital rubella syndrome:</b> </p> <p>We included RCTs, quasi‐RCTs and prospective controlled studies (cohort studies) that examined either or both of these outcomes, irrespective of blinding, publication status, language or unit of randomisation. We included prospective controlled studies for these outcomes given that pregnant women would ethically not have been randomised to treatment and control groups, given that this intervention was felt to be beneficial from the time it was first used. </p> <p>To be considered an eligible prospective controlled study, the intervention and control groups of relevance needed to be recruited over the same (or similar and overlapping) timeframe and from the same population and the study must have specified that the intervention and control populations of relevance were exposed to rubella during pregnancy and were susceptible to rubella at the time of exposure. We excluded the study if any of these points could not be determined from the information available either in the publication or from the study authors. </p> <p><b>To assess adverse events:</b> </p> <p>We included data on adverse events from any of the studies included in the review as above. </p> </section> <section id="CD010586-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants were people of any age, sex or ethnic origin who were susceptible (no history of rubella and not vaccinated against rubella and/or rubella IgG negative) and exposed to rubella virus or exposed to someone diagnosed with rubella and who did not already have rubella at the time of intervention or control administration. We accepted the primary study's definition of exposed and explored any differences via subgroup analysis. For the congenital rubella infection and congenital rubella syndrome outcomes, participants must have been pregnant at the time of rubella exposure. </p> </section> <section id="CD010586-sec-0033"> <h4 class="title">Types of interventions</h4> <p><b>To assess the effectiveness of polyclonal immunoglobulins for preventing cases of rubella:</b> </p> <p>Intervention:</p> <p> <ol id="CD010586-list-0001"> <li> <p>intramuscular injection of polyclonal immunoglobulins;</p> </li> <li> <p>intravenous infusion of polyclonal immunoglobulins.</p> </li> </ol> </p> <p>Control:</p> <p> <ol id="CD010586-list-0002"> <li> <p>no intervention or placebo;</p> </li> <li> <p>live attenuated rubella virus vaccine;</p> </li> <li> <p>different preparation and/or dosage of polyclonal immunoglobulins.</p> </li> </ol> </p> <p><b>To assess the effectiveness of polyclonal immunoglobulins for preventing congenital rubella infection and congenital rubella syndrome:</b> </p> <p>Intervention:</p> <p> <ol id="CD010586-list-0003"> <li> <p>intramuscular injection of polyclonal immunoglobulins;</p> </li> <li> <p>intravenous infusion of polyclonal immunoglobulins.</p> </li> </ol> </p> <p>Control:</p> <p> <ol id="CD010586-list-0004"> <li> <p>no intervention or placebo;</p> </li> <li> <p>different preparation and/or dosage of polyclonal immunoglobulins.</p> </li> </ol> </p> <p>For all outcomes, polyclonal immunoglobulins must have originated from human plasma or serum. We excluded studies of immunoglobulins of animal origin and studies of immunoglobulins derived from placentas or given as human whole blood as these are not used in modern day practice. </p> </section> <section id="CD010586-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010586-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010586-list-0005"> <li> <p>Cases of rubella. The diagnosis may have been made by detection or isolation of rubella virus in urine, respiratory secretions or blood; by rubella‐specific IgG seroconversion or a four‐fold or greater rise in titre; by serological detection of IgM to rubella in the presence of a compatible clinical illness and no recent vaccination; or by symptoms consistent with rubella (fever, a generalised maculopapular rash and one or more of arthralgia/arthritis, lymphadenopathy, conjunctivitis) in the absence of other diagnoses as judged by a medical professional. </p> </li> <li> <p>Cases of congenital rubella infection. The diagnosis may have been made by detection or isolation of rubella virus in the infant's urine, respiratory secretions or blood or in the products of conception; by serological detection of rubella‐specific IgM in the infant's serum; or by rising rubella‐specific IgG in the infant's serum in the first year of life. </p> </li> <li> <p>Cases of congenital rubella syndrome. A live or stillborn infant with any of the following compatible defects: cataracts, congenital glaucoma, congenital heart disease, hearing impairment, pigmentary retinopathy, microcephaly, mental retardation, purpura, hepatosplenomegaly, meningoencephalitis, radiolucent bone disease; and evidence of congenital rubella infection or maternal antepartum rubella infection. </p> </li> </ol> </p> </section> <section id="CD010586-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010586-list-0006"> <li> <p>Occurrence of serious adverse events.</p> </li> <li> <p>Occurrence of non‐serious adverse events.</p> </li> </ol> </p> <p>A serious adverse event was defined as "any untoward medical occurrence that at any dose: results in death; is life‐threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect" (<a href="./references#CD010586-bbs2-0157" title="European Medicines Agency. ICH Topic E 2 A ‐ clinical safety data management: definitions and standards for expedited reporting. 1995. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf (accessed 10 June 2012). ">EMEA 1995</a>; p4). We classified all other events as non‐serious. </p> <p>We specifically extracted data on blood‐borne virus infection; anaphylaxis (a rapidly evolving generalised multi‐system allergic reaction characterised by one or more symptoms or signs of respiratory and/or cardiovascular involvement AND involvement of other systems such as skin or gastrointestinal tract (<a href="./references#CD010586-bbs2-0141" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 9th Edition. Canberra: Australian Government, 2008. ">ATAGI 2008</a> p360); generalised hypersensitivity/generalised allergic reaction (non‐anaphylactic generalised reaction characterised by one or more symptoms or signs of skin and/or gastrointestinal tract involvement without respiratory or cardiovascular involvement (<a href="./references#CD010586-bbs2-0141" title="Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 9th Edition. Canberra: Australian Government, 2008. ">ATAGI 2008</a> p360); and injection site reactions. We also included any other adverse event reported as such by study authors. </p> </section> </section> </section> <section id="CD010586-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010586-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 7), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (OVID) (1946 to August week 2, 2014), CINAHL (1981 to August 2014), EMBASE (1974 to August 2014), LILACS (1982 to August 2014) and Web of Science (1955 to August 2014). We used the search strategy in <a href="./appendices#CD010586-sec-0087">Appendix 1</a> to search MEDLINE and CENTRAL. We adapted the strategy for EMBASE (<a href="./appendices#CD010586-sec-0088">Appendix 2</a>), CINAHL (<a href="./appendices#CD010586-sec-0089">Appendix 3</a>), LILACS (<a href="./appendices#CD010586-sec-0090">Appendix 4</a>) and Web of Science (<a href="./appendices#CD010586-sec-0091">Appendix 5</a>). We combined the MEDLINE and EMBASE searches with the filter for study type in <a href="./appendices#CD010586-sec-0092">Appendix 6</a>. </p> </section> <section id="CD010586-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved relevant studies and reviews. To locate further published or unpublished studies, we attempted to contact companies manufacturing IG products for countries with low rubella incidences and also attempted to contact the corresponding author of any included studies. We searched the reference lists of published national public health guidelines on rubella control. We searched ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry (WHO ICTRP) using the terms "rubella" OR ("German" AND "measles") on 16 October 2014. </p> </section> </section> <section id="CD010586-sec-0040"> <h3 class="title" id="CD010586-sec-0040">Data collection and analysis</h3> <section id="CD010586-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MY, GN) independently inspected the title and abstract (as available) of each reference identified by the electronic searches and determined the potential relevance of each article. If identified by either review author as potentially relevant, we retrieved the full article. One review author (MY) searched the trials databases and the reference lists of relevant retrieved full‐text articles for further studies. We retrieved these articles where the title indicated possible relevance and exclusion was not possible based on the abstract where this was available. Both review authors inspected each retrieved full‐text article independently, using an eligibility checklist based on the inclusion criteria, to determine inclusion in the review. We resolved any disagreements through discussion. We excluded studies not meeting the eligibility criteria and stated the reasons for exclusion. Among the articles retrieved in full text, we found several studies where the design was a controlled clinical trial (CCT) (with exposure to rubella virus controlled by the investigators) but the method of allocation of participants to groups was not reported. An alternative report of one of these studies indicated participants were assigned to groups randomly, therefore we mutually agreed to include such studies and then undertake sensitivity analysis. </p> <p>We listed duplicate publications with the main publication for included studies. </p> </section> <section id="CD010586-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MY, AC) independently extracted data from the included studies using pre‐designed data extraction forms. We resolved disagreement by discussion. We attempted to contact study authors for clarification or further information as necessary.   </p> <p>We extracted the following data.</p> <p> <ol id="CD010586-list-0007"> <li> <p>The study</p> <ol id="CD010586-list-0008"> <li> <p>First author, publication year/not published.</p> </li> <li> <p>Setting of the study.</p> </li> <li> <p>Date study undertaken.</p> </li> <li> <p>Study design: RCT, quasi‐RCT, CCT or non‐randomised.</p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD010586-list-0009"> <li> <p>Number in each group.</p> </li> <li> <p>Age range in each group.</p> </li> <li> <p>Gender distribution in each group.</p> </li> <li> <p>Range of gestation in each group if relevant.</p> </li> <li> <p>Range of time since exposure in each group.</p> </li> <li> <p>Average time since exposure in each group.</p> </li> <li> <p>Any measure of baseline comparability and result of this, if calculated.</p> </li> </ol> </li> <li> <p>Intervention</p> <ol id="CD010586-list-0010"> <li> <p>Intervention group: product used, concentration of rubella antibody if known, volume given, route of administration. </p> </li> <li> <p>Control group: placebo/vaccine/product/other, concentration of rubella antibody if relevant and known, volume given, route of administration. </p> </li> </ol> </li> <li> <p>Outcomes</p> <ol id="CD010586-list-0011"> <li> <p>Primary and secondary (as above).</p> </li> <li> <p>Length of follow‐up.</p> </li> <li> <p>Loss to follow‐up.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD010586-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MY, AC) independently assessed the risk of bias for included studies. We resolved any disagreements by discussion.  </p> <p>The 12 included studies were either RCTs or controlled clinical trials (CCTs) where the means of allocation of participants to groups was not reported. An alternative report of one of these latter studies indicated that participants were assigned to groups randomly, therefore we included such studies as meeting the criteria for RCTs/quasi‐RCTs. </p> <p>We therefore assessed randomisation sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; drop‐out/selective reporting; and other potential sources of bias. We reported the risk of bias using The Cochrane Collaboration's tool for assessing 'Risk of bias' (<a href="./references#CD010586-bbs2-0164" title="HigginsJ , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane‐handbook.org. ">Higgins 2011</a>).  </p> <p>We conducted sensitivity analyses based on the study type and the risk of bias of included studies. We reported these results descriptively. </p> </section> <section id="CD010586-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We undertook data analyses in RevMan 5.3 (<a href="./references#CD010586-bbs2-0181" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Outcomes, as identified above, are dichotomous. We expressed these outcomes as risk ratios (RR) and calculated 95% confidence intervals (CIs) for each. </p> </section> <section id="CD010586-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>Our protocol specified that should cluster‐randomised trials be included in the review, we would attempt to extract RRs and 95% CIs resulting from analyses that have accounted for the clustering directly from the article/s. If this had been possible, we would have proceeded to meta‐analyse the data using the inverse variance method. If this had not been possible, we would have extracted the number of clusters, the average size of each cluster, the outcome data at the level of the individuals and an estimate of the intra cluster correlation coefficient and proceeded to reduce the trial/s to their 'effective sample size' for meta‐analysis following the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010586-bbs2-0164" title="HigginsJ , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane‐handbook.org. ">Higgins 2011</a>). However, we did not identify any cluster‐randomised trials that met our inclusion criteria. </p> <p>Our protocol specified that should studies with multiple intervention groups, for example, different doses of immunoglobulins compared to control, be included in the review, we would initially split the shared group/s and include the relevant pair‐wise comparisons in the meta‐analysis (<a href="./references#CD010586-bbs2-0164" title="HigginsJ , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane‐handbook.org. ">Higgins 2011</a>). Then, if there was no significant heterogeneity between the different interventions/controls from the same study, we would combine the groups and include the single intervention and single control group in the final meta‐analysis, or if significant heterogeneity existed, we would explore the differences in subgroup analyses. However, we did not identify any studies with multiple intervention groups, for example, different doses of immunoglobulins compared to control, which met our inclusion criteria. </p> </section> <section id="CD010586-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Our protocol specified that we would attempt to contact the trial authors for any missing data. Then, for remaining missing data we would analyse using the intention‐to‐ treat (ITT) principle with all missing data considered treatment failures. If we undertook ITT analysis, we would undertake sensitivity analysis assuming worst‐case (all missing data are treatment failures) and best‐case scenarios (missing data assigned as successful as in reported data or last observation carried forward or all missing data considered successful). However, for all included studies, follow‐up of participants was complete. </p> </section> <section id="CD010586-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered heterogeneity firstly by considering the populations, settings, methods and outcomes of the different studies. We were not able to undertake meta‐analysis for the primary outcomes 'congenital rubella infection' (no studies assessed this outcome) and 'congenital rubella syndrome' (only one study assessed this outcome). We described the results of the study assessing congenital rubella syndrome descriptively. We did not identify clinically important heterogeneity that would have required reporting results descriptively for the primary outcome 'rubella cases', so we inspected the forest plot for this outcome.  As per our protocol, we considered an I<sup>2</sup> statistic estimate of 60% or more, alongside a Chi<sup>2</sup> test P value of 0.1 or less to indicate important heterogeneity and proceeded to subgroup and sensitivity analyses. </p> </section> <section id="CD010586-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>In the event of multiple publications of the same study, we listed the subsequent articles with the main article and only entered data once.  </p> <p>Our protocol indicated that we would assess publication bias by examining funnel plots if sufficient studies (at least 10) were included. However, our final meta‐analysis included only seven studies. Further, all included studies had fairly small sample sizes. The largest study was of 179 participants. </p> </section> <section id="CD010586-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We calculated the RRs and 95% CI for each outcome measured in each study. </p> <p>We initially included all studies relevant to the outcome subject to meta‐analysis and examined the forest plot to assess heterogeneity. We explored possible reasons for apparent heterogeneity via subgroup and sensitivity analyses. As per our protocol, we pooled the results using a fixed‐effect model.  </p> <p>We reported the results of those outcomes where meta‐analysis was not undertaken descriptively. We reported the results of the secondary outcomes descriptively. </p> </section> <section id="CD010586-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Our protocol listed the following subgroup analysis that we were unable to perform:</p> <p> <ul id="CD010586-list-0012"> <li> <p>dose of rubella‐specific immunoglobulins (most studies reported rubella‐specific antibody titres for the immunoglobulin product/s used, however, none of the included studies reported the rubella‐specific antibody concentration in international units or reported using an internationally recognised standard control when assessing this measure. It was thus not possible to compare and categorise the products used into similar rubella‐specific antibody concentrations.) </p> </li> </ul> </p> <p>Further, the following subgroup analyses were not relevant to the review:</p> <p> <ul id="CD010586-list-0013"> <li> <p>stage of gestation (trimester of pregnancy) (none of the studies included in meta‐analyses included pregnant participants); </p> </li> <li> <p>route of administration of immunoglobulins (all except <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a> administered IG via the intramuscular route); </p> </li> <li> <p>per protocol versus ITT analysis (to account for missing data) (participant follow‐up was complete for all studies). </p> </li> </ul> </p> <p>We undertook the following subgroup analyses as identified in our protocol:</p> <p> <ul id="CD010586-list-0014"> <li> <p>study type (CCT and RCT);</p> </li> <li> <p>age of participants (children, adults, mixed) (adults were defined using the widely accepted, legal 'age of majority' definition for most countries (<a href="./references#CD010586-bbs2-0196" title="World LawDirect . Age of majority. [Law Wiki forum]. Available from: http://www.worldlawdirect.com/forum/law‐wiki/27181‐age‐majority.html 2009 (accessed 29 April 2015). ">World Law Direct 2009</a>; <a href="./references#CD010586-bbs2-0197" title="ZeldinW . International Laws: Children's Rights. [Law Library of Congress report]. Available from: http://www.loc.gov/law/help/child‐rights/pdfs/Children's%20Rights‐International%20Laws.pdf 2007 (accessed 29 April 2015). ">Zeldin 2007</a>), 18 years and over); </p> </li> <li> <p>dose of immunoglobulins (0.027 to 0.037 ml/lb; 0.1 to 0.15 ml/lb; 0.2 to 0.5 ml/lb). In those studies where the same volume was administered to each adult participant and participant weights were not reported (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), the volume administered by weight was estimated using 70 kg (154 lb) as the weight of an adult. Similarly, the 50th percentile weight for age for males according to current Australian growth charts (<a href="./references#CD010586-bbs2-0173" title="New South Wales Health. My Personal Health Record. Available at: http://www.kidsfamilies.health.nsw.gov.au/publications/child‐personal‐health‐record‐(blue‐book)/ 2014 (accessed 27 July 2014). ">NSW Health 2014</a>) was used (126 to 150 lb) for the study where participants were adolescent boys aged 15 to 18 years in Australia but no participant weights were reported (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>). We then determined dose categories by visually assessing the number and range of volumes per pound administered in the different studies. We excluded <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> because the amount of IG given was given in milligrams instead of as a volume; </p> </li> <li> <p>timing of administration of intervention in relation to exposure (exposure 24 hours to five days prior to IG; and exposure up to eight to 28 days prior to IG) (we excluded <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a> and <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> because the timing of the intervention in relation to exposure was not reported); </p> </li> <li> <p>differences in primary study definitions of 'exposed' (artificial exposure; controlled exposure to an infected person; household contact with a diagnosed case) (we excluded <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> because the nature of exposure was not reported); </p> </li> <li> <p>differences in primary study measurement of outcomes (laboratory‐confirmed; and cases defined on clinical grounds only) (we excluded <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> because no information was reported on how rubella cases were assessed); </p> </li> <li> <p>funder (those with potential conflict of interest (gamma‐globulin provided by a company); and no known conflict of interest) (we included <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a> in the subgroup "no known conflict of interest" but we noted that the funding source was not reported). </p> </li> </ul> </p> </section> <section id="CD010586-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses as per our protocol to assess the impact of heterogeneity and risk of bias on the pooled estimate/s of meta‐analyses. For heterogeneity, we gradually removed single trials that seemed to contribute to heterogeneity upon inspection of the forest plots. For risk of bias, we pooled the studies with the lowest risk of bias and then gradually added the studies assessed as having a higher risk of bias. </p> <p>We undertook additional sensitivity analyses because of the inclusion of controlled clinical trials where the means of allocation of participants was not reported and because we noted some included studies used history only to assess susceptibility for rubella whereas the majority identified those susceptible according to serology. We gradually removed the controlled clinical trials from the analysis firstly in order of the magnitude of the effect estimate (largest to smallest) and then separately in order of the size of the trial (largest to smallest). We simultaneously removed the three studies that used history only to assess susceptibility of participants to rubella at the beginning of the respective trials. </p> <section id="CD010586-sec-0052"> <h5 class="title">Overall quality of the evidence</h5> <p>We used the GRADE approach to assess the overall quality of the evidence (<a href="./references#CD010586-bbs2-0161" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group 2004</a>). One author (MY) entered the information into GRADEpro (<a href="./references#CD010586-bbs2-0162" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. Available from www.gradepro.org. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro 2015</a>) and produced the 'Summary of findings' table for the primary outcomes and adverse events (<a href="./full#CD010586-tbl-0001">summary of findings Table for the main comparison</a>). For the primary outcome 'Rubella cases', we included both the initial meta‐analysis and the final (subgroup analysis that explained heterogeneity) meta‐analysis results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010586-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010586-sec-0053"></div> <section id="CD010586-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD010586-sec-0055"> <h4 class="title">Results of the search</h4> <p>The number of search results obtained from each database prior to duplicate removal was CENTRAL (168), MEDLINE (1664), EMBASE (747), CINAHL (78), LILACS (120) and Web of Science (563). Of these, we retrieved 71 full‐text articles resulting in eight included studies. </p> <p>Searching the reference lists of relevant retrieved full‐text articles identified a further 79 unique records, of which we retrieved 69 full‐text articles resulting in four additional included studies (<a href="#CD010586-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010586-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010586-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Searching ClinicalTrials.gov returned 108 records and WHO ICTRP returned 157 records. We did not identify any additional relevant studies. </p> <p>We sent electronic written requests to 13 separate companies that manufacture immunoglobulin products (<a href="./appendices#CD010586-sec-0094">Appendix 8</a>) and the Australian Technical Advisory Group on Immunisation (ATAGI). Six companies and ATAGI responded. We did not identify any additional relevant studies. </p> <p>We searched the reference lists of 18 documents we identified as published national public health guidelines on rubella control (<a href="./appendices#CD010586-sec-0095">Appendix 9</a>). We did not identify any additional relevant studies. </p> <p>The age of the included studies and absent up‐to‐date contact details for authors meant that we were not able to contact the authors of any included studies. </p> </section> <section id="CD010586-sec-0056"> <h4 class="title">Included studies</h4> <p>We included 12 studies in the review: seven RCTs and five presumed RCTs (see <a href="./references#CD010586-sec-0103" title="">Characteristics of included studies</a>). In these last five studies, susceptible participants were intentionally exposed to rubella virus by the investigators. Included studies were published between 1953 and 1978. We included no unpublished studies. </p> <p>Included studies were undertaken in five different countries: the United States (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), United Kingdom (<a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>), Germany (<a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>), Switzerland (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>), and Australia (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>). A total of 430 participants were recruited from the community, different residential institutions, universities and medical settings. Sample sizes ranged from seven to 179. </p> <p>Six studies included only adult participants (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), and four studies included only children (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). One study included adolescents (aged 15 to 18 years) (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>). One study included children and adults (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). The entire study population for this study included participants aged three to 50+ years, however only results from those who were known to be susceptible to rubella were included in the review. This group was aged three to 19 years. </p> <p>Three studies included only male participants (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), two studies included only female participants (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>), and the remainder did not report the gender distribution of their participants. Participants in one of the all‐female studies were fewer than nine weeks pregnant (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>). </p> <p>Susceptibility was defined as no history of rubella infection by three studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). The remainder determined susceptibility by serology. </p> <p>Participants were artificially exposed to rubella virus in five studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>). In three studies, participants were exposed under controlled conditions to children who had been artificially exposed and were known to be infected with rubella virus (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>). In two studies, participants were living with diagnosed cases of rubella (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). Participants self reported exposure in one study (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>) and in one study, no detail was given on the means of exposure (<a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). </p> <p>The time between exposure and intervention ranged from 24 hours to five days in the studies where exposure was via inoculation with the virus (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>). <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a> controlled the time of exposure to a known case and administered immunoglobulin 24 hours after exposure. The interval between exposure and intervention was much less precise (up to 11 days ‐ <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; up to eight days ‐ <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; up to four weeks ‐ <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>) and unknown or not reported (<a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>) for the other studies. </p> <p>The intervention was gamma‐globulin given intramuscularly in 10 studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>). Gamma‐globulin was given intravenously in one study (30 ml to 60 ml diluted in 200 ml saline) (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>), and 'poliomyelitis immune globulin' with a rubella antibody concentration of 1:300 was given intramuscularly in one study (at 0.5 ml per unit of bodyweight ‐ unit not specified) (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). Of those administering gamma‐globulin intramuscularly: three studies dosed by weight (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>) at 0.15 ml to 0.2 ml per pound, three studies administered 20 ml (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), two studies administered 4 ml (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>), one study administered 15 ml after giving 20 ml six weeks earlier to the same participants (<a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>), and one study administered 250 mg (<a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). </p> <p>None of the included studies reported antibody titres of the immunoglobulin products used in international units. The rubella antibody titre of the immunoglobulin product used was not reported in three studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). Three studies reported a rubella antibody titre as assessed by hemagglutinin inhibition: one had a titre of 512 (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>), one had a titre of 1000 (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>), and one had a titre of 2560 (<a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>). Five studies reported rubella antibody titre as assessed by neutralisation assay: one had a titre of 1024/0.1 ml (<a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>), one had a titre of 256/0.1 ml (<a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), two had titres of 64 (<a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>), and one had a titre of 32 (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>). One study reported rubella antibody titre but did not report the means by which it was assessed. The reported titre was 1:300 (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). </p> <p>Of the studies trialing intramuscular gamma‐globulin, six used 'no treatment' control groups (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>), three gave saline of the same volume as the intervention intramuscularly to the control group (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a>; <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a>), and one gave gamma‐globulin intramuscularly in the same volume but of a lower rubella antibody titre (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>). The study trialing intravenous gamma‐globulin used a 'no treatment' control group (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>), as did the study trialing 'poliomyelitis immune globulin' (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). </p> <p>All included studies assessed the number of rubella cases in each group as the primary outcome. Serological survey with or without other laboratory testing was undertaken to determine rubella infection in all but three studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). Cases were determined on clinical grounds only by two of these studies (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>). <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> did not report how participants were assessed for rubella infection. One study assessed cases of congenital rubella syndrome (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>). No studies assessed cases of congenital rubella infection. No studies assessed or reported on adverse events. </p> <p>In three studies, the intervention product used was supplied by a company. These were: Red Cross Blood Transfusion Service and CSL, Australia (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>), and Parke, Davis &amp; Co, Detroit (<a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>). The study by <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a> was also supported by a US Public Health Service infectious diseases training grant. <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>, <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a> and <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a> were funded by a grant from the National Institute of Allergy and Infectious Diseases, US Public Health Service and a contract with the US Army Medical Research and Development Command, Office of the Surgeon General. <a href="./references#CD010586-bbs2-0011" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969a</a> and <a href="./references#CD010586-bbs2-0012" title="SchiffGM . The efficacy of titred lots of immune globulin (IG) in preventing rubella. In International Symposium on Rubella Vaccines, London 1968. Symposium Series Immunobiology Standard1969;11:83‐94. SchiffGM . Titered lots of immune globulin (Ig). Efficacy in the prevention of rubella. American Journal of Diseases of Children1969;118(2):322‐7. ">Schiff 1969b</a> were supported by the 'National Foundation' and a 'Career Research Development Award from the National Institutes of Health'. <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>, <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>, <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> and <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a> did not report any sources of funding. </p> </section> <section id="CD010586-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 129 of the 140 articles retrieved in full text. The reasons for exclusion of individual articles are given in the <a href="./references#CD010586-sec-0104" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD010586-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Five studies where exposure to rubella was controlled by the investigators did not specify that participants were allocated randomly to groups (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>). However, an alternative report of a study initially categorised with these studies did specify that participants were assigned to groups randomly and hence we included these studies in the review as meeting criteria for RCTs/quasi‐RCTs. </p> <p>No study was at low risk of bias for all criteria (<a href="#CD010586-fig-0002">Figure 2</a>; <a href="#CD010586-fig-0003">Figure 3</a>; <a href="./references#CD010586-sec-0103" title="">Characteristics of included studies</a>). The quality of the 11 studies in the initial meta‐analysis was moderate (<a href="./full#CD010586-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD010586-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010586-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010586-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010586-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010586-sec-0059"> <h4 class="title">Allocation</h4> <p>Random sequence generation and the means of allocation concealment was not reported in any included study. We thus assessed all to have unclear risk of bias for this criteria. </p> </section> <section id="CD010586-sec-0060"> <h4 class="title">Blinding</h4> <p>The intervention, administration of polyclonal immunoglobulins, is very unlikely to be subject to variation due to performance and, as such, we deemed all studies at low risk of performance bias. </p> <p>We assessed detection bias for the outcomes cases of rubella and cases of congenital rubella syndrome, as no study examined the outcome cases of congenital rubella infection. The study that assessed cases of congenital rubella syndrome did not report whether participants or outcome assessors were blinded, although the control group was given gamma‐globulin of a lower rubella antibody titre at the same volume as the intervention group (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>). There was no reported definition of congenital rubella syndrome nor method of assessment of the infants of participants. Infants of participants were followed up for between six months and three years but it was not reported whether there was a difference in average length of follow‐up between groups. Due to the lack of information on the methodology, we assessed the study as at an unclear risk of detection bias for cases of congenital rubella syndrome. The same study defined cases of maternal rubella by seroconversion. This objective measure led us to assess this study as being of low risk of detection bias for the outcome cases of rubella. </p> <p>We deemed two studies at high risk of detection bias in relation to cases of rubella (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). This was because no blinding was reported and the outcome was assessed by means of clinical signs. We deemed <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a> at low risk of detection bias for rubella cases. Although the outcome was measured clinically, both the participants and the outcome assessor were blinded. We assessed the remaining studies as at low risk of detection bias for cases of rubella because, irrespective of blinding, the outcome was objectively measured. </p> </section> <section id="CD010586-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>All studies reported complete follow‐up for cases of rubella. <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a> had complete clinical follow‐up and complete follow‐up of the subset of participants from whom oropharyngeal swabs were collected but did report collection of paired sera on 43 of the 47 participants in the subgroup (91.5%). <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a> reported complete follow‐up for cases of congenital rubella syndrome. We deemed all studies at low risk of attrition bias. </p> </section> <section id="CD010586-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Among the three studies reported by Green et al, <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>, <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a> and <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>, is a comparison of the results of serum samples tested for viraemia on a subset of five intervention participants and five control participants. The methods indicate that nasopharyngeal swabs were collected from participants but do not include details of serum sampling. We deemed these studies at high risk of reporting bias. Each of the other included studies reported on all outcomes specified in the methods sections and we deemed them to be at low risk of reporting bias. </p> </section> <section id="CD010586-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We were unable to examine a funnel plot to assess for publication bias as there were only seven studies in the analysis that explained the heterogeneity of the original pooled result. However, small study effects were unlikely in our review given the only study with an independently statistically significant result was the largest study. </p> </section> </section> <section id="CD010586-sec-0064"> <h3 class="title" id="CD010586-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD010586-tbl-0001"><b>Summary of findings for the main comparison</b> Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</a> </p> <section id="CD010586-sec-0065"> <h4 class="title">Primary outcomes  </h4> <section id="CD010586-sec-0066"> <h5 class="title">1. Cases of rubella</h5> <p>We entered 11 of the 12 included studies into a meta‐analysis of the primary outcome 'cases of rubella'. The result favoured the intervention group (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.45 to 0.83) but was heterogenous (Chi² test = 36.59, df = 10 (P value &lt; 0.0001); I² statistic = 73%) (<a href="./references#CD010586-fig-0004" title="">Analysis 1.1</a>). </p> <p>We excluded <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a> from this meta‐analysis due to heterogeneity of the control group (a lower titre gamma‐globulin was given to the controls) as compared to the other studies ('do nothing' or placebo in the form of saline). The result of this study also favoured the intervention group although it was not statistically significant (RR 0.70, 95% CI 0.13 to 3.76). </p> <section id="CD010586-sec-0067"> <h6 class="title">Subgroup analyses</h6> <p>Subgrouping studies by study type (<a href="./references#CD010586-fig-0005" title="">Analysis 1.2</a>) did not explain the heterogeneity (overall heterogeneity: Chi² test = 36.59, df = 10 (P value &lt; 0.0001); I² statistic = 73%) and we found no difference between the subgroup estimates of effect (test for subgroup differences: Chi² test = 0.09, df = 1 (P value = 0.77), I² statistic = 0%). </p> <p>Subgrouping studies according to age group (adults, children, mixed) (<a href="./references#CD010586-fig-0006" title="">Analysis 1.3</a>) did not explain the heterogeneity (overall heterogeneity: Chi² test = 36.59, df = 10 (P value &lt; 0.0001); I² statistic = 73%) and we found no difference between the subgroup estimates of effect (test for subgroup differences: Chi² = 1.09, df = 2 (P value = 0.58), I² = 0%). </p> <p>Subgrouping studies according to categories of estimated dose of immunoglobulins (<a href="./references#CD010586-fig-0007" title="">Analysis 1.4</a>) somewhat reduced heterogeneity (overall heterogeneity: Chi² test = 21.92, df = 9 (P value = 0.009); I² statistic = 59%). The subgroup 'estimated 0.1 to 0.15 ml/lb' did not demonstrate significant heterogeneity, while the other two subgroups did ('estimated 0.027 to 0.037 ml/lb', heterogeneity: Chi² test = 3.07, df = 1 (P value = 0.08); I² statistic = 67%; 'estimated 0.2 to 0.5 ml/lb' heterogeneity: Chi² test = 16.48, df = 3 (P value = 0.0009); I² statistic = 82%). There was no difference in the estimates of effect between subgroups (test for subgroup differences: Chi² test = 0.12, df = 2 (P value = 0.94), I² statistic = 0%). The overall estimate of effect was smaller than the original meta‐analysis (overall RR 0.70, 95% CI 0.52 to 0.95). </p> <p>Subgrouping studies according to categories of time between exposure to rubella and intervention (<a href="./references#CD010586-fig-0008" title="">Analysis 1.5</a>) somewhat reduced heterogeneity (overall heterogeneity: Chi² test = 20.07, df = 8 (P value = 0.01); I² statistic = 60%). The subgroup 'Exposure 24 hours to five days prior to IG' did not demonstrate significant heterogeneity (heterogeneity: Chi² test = 7.84, df = 5 (P value = 0.17); I² statistic = 36%), while the subgroup 'Exposure up to eight to 28 days prior to IG' did (heterogeneity: Chi² = 6.65, df = 2 (P value = 0.04); I² statistic = 70%). There was no difference in the estimates of effect between the subgroups (test for subgroup differences: Chi² test = 0.62, df = 1 (P value = 0.43), I² statistic = 0%). The overall estimate of effect was smaller than the original meta‐analysis (overall RR 0.72, 95% CI 0.53 to 0.97). </p> <p>Subgrouping studies according to the study definition of exposure (<a href="./references#CD010586-fig-0009" title="">Analysis 1.6</a>) somewhat reduced heterogeneity (overall heterogeneity: Chi² test = 21.92, df = 9 (P value = 0.009); I² statistic = 59%). No significant heterogeneity was demonstrated for the subgroups 'Artificial exposure' and 'Controlled exposure to an infected person'. The subgroup 'Household contact with a diagnosed case' demonstrated significant heterogeneity (heterogeneity: Chi² test = 10.81, df = 1 (P value = 0.001); I² statistic = 91%). There was no difference in the estimates of effect between the subgroups (test for subgroup differences: Chi² test = 0.29, df = 2 (P value = 0.86), I² statistic = 0%). The overall estimate of effect was smaller than the original meta‐analysis (overall RR 0.70, 95% CI 0.52 to 0.95). </p> <p>Subgrouping studies according to the definition of rubella cases (<a href="./references#CD010586-fig-0010" title="">Analysis 1.7</a>) somewhat reduced heterogeneity (overall heterogeneity: Chi² test = 21.92, df = 9 (P value = 0.009); I² statistic = 59%), although both subgroups still demonstrated significant heterogeneity and there was no difference in the estimates of effect between subgroups (test for subgroup differences: Chi² test = 0.10, df = 1 (P value = 0.75), I² statistic = 0%). The overall estimate of effect was smaller than the original meta‐analysis (overall RR 0.70, 95% CI 0.52 to 0.95). </p> <p>Subgrouping studies according to funder (<a href="./references#CD010586-fig-0011" title="">Analysis 1.8</a>) demonstrated a difference between the subgroups (test for subgroup differences: Chi² test = 4.21, df = 1 (P value = 0.04), I² statistic = 76.3%). The studies classified as having funding with potential conflict of interest were homogenous according to our protocol‐specified definition (heterogeneity: Chi² test = 4.52, df = 2 (P value = 0.10); I² statistic = 56%) and had a pooled estimate of effect of RR 0.87 (95% CI 0.57 to 1.33). The subgroup with no known funder with a potential conflict of interest was heterogenous (heterogeneity: Chi² test = 17.58, df = 7 (P value = 0.01); I² statistic = 60%) and had a pooled estimate of effect of RR 0.46 (95% CI 0.29 to 0.72). Three studies included in the subgroup without known conflict of interest did not report funder information (<a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>). Excluding these studies reduced the difference between the subgroups so that it was no longer significant (test for subgroup differences: Chi² test = 1.25, df = 1 (P value = 0.26), I² statistic = 19.9%), but did not reverse the direction of the difference (no known conflict of interest subgroup RR 0.60, 95% CI 0.35 to 1.00). </p> </section> <section id="CD010586-sec-0068"> <h6 class="title">Post hoc subgroup analysis</h6> <p>It is well established that the most important factors that impact on the effectiveness of post‐exposure passive immunisation for other viral infections such as measles and hepatitis A are the dose of immunoglobulins administered and the time between exposure and intervention (<a href="./references#CD010586-bbs2-0178" title="RamsayM , ManikkavasaganG , BrownK , CraigL . Post exposure prophylaxis for measles: revised guidance May 2009. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/322634/Post_exposure_prophylaxis_for_measles.pdf 2009 (accessed 29 April 2015). ">Ramsay 2009</a>; <a href="./references#CD010586-bbs2-0189" title="Thomas L and the Hepatitis A Guidelines Group. Guidance for the Prevention and Control of Hepatitis A Infection. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/363023/Guidance_for_the_Prevention_and_Control_of_Hepatitis_A_Infection.pdf 2009 (accessed 23 March 2015). ">Thomas 2009</a>). Given the variability in both of these factors across the included studies, we undertook a post hoc analysis to consider these simultaneously. The limited number of included studies meant that these factors could not be explored in a combined subgroup analysis. However, removing those studies where the time between exposure and intervention was up to eight to 28 days (<a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>) from the subgroup analysis that explored the impact of dose on effectiveness (<a href="./references#CD010586-fig-0007" title="">Analysis 1.4</a>) explained the heterogeneity within the subgroups and demonstrated a difference between subgroups (test for subgroup differences: Chi² test = 5.32, df = 2 (P value = 0.07), I² statistic = 62.4%). The estimates of effect were: 'estimated 0.027 to 0.037 ml/lb' RR 1.60 (95% CI 0.57 to 4.52); 'estimated 0.1 to 0.15 ml/lb' RR 0.53 (95% CI 0.29 to 0.99); and 'estimated 0.2 to 0.5 ml/lb' RR 0.20 (95% CI 0.04 to 1.00) (<a href="./references#CD010586-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD010586-sec-0069"> <h6 class="title">Sensitivity analyses</h6> <p>As seen in <a href="#CD010586-fig-0002">Figure 2</a>, five studies were at a higher risk of bias than the others (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). We deemed each of these at high risk of bias for one item. Excluding these from the original pooled analysis marginally altered the estimate of effect away from the null (RR 0.58, 95% CI 0.40 to 0.83; heterogeneity: Chi² test = 30.82, df = 5 (P value &lt; 0.0001), I² statistic = 84%). Returning the three studies at high risk of selective reporting (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>) marginally altered this result toward the null (RR 0.62, 95% CI 0.45 to 0.86), while returning instead the two studies at high risk of detection bias (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>) did not alter the result (RR 0.58, 95% CI 0.41 to 0.81). </p> <p>Three studies assessed susceptibility to rubella on history alone (<a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>). Removing these studies from the meta‐analysis marginally reduced the size of the effect estimate (RR 0.68, 95% CI 0.50 to 0.92). Heterogeneity was still apparent (heterogeneity: Chi² test = 21.24, df = 7 (P value = 0.003); I² statistic = 67%). </p> <p>Five studies did not specify how participants were allocated to groups (<a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; <a href="./references#CD010586-bbs2-0005" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965b</a>; <a href="./references#CD010586-bbs2-0006" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965c</a>; <a href="./references#CD010586-bbs2-0007" title="Martin du PanR , KoechliB , DouathA . Protection of nonimmune volunteers against rubella by intravenous administration of normal gamma globulin. Journal of Infectious Diseases1972;126(3):341‐4. ">Martin du Pan 1972</a>; <a href="./references#CD010586-bbs2-0010" title="PetersenEE , Neumann‐HaefelinD , HeusslerM . Rubella in pregnancy: experimental studies on the value of gamma‐globulin after rubella wild virus infection [Rotelninfektion in der schwangerschaft: experimentelle studie zum wert einer gammaglobulingabe nach rotelnwildvirusinfektion]. Deutsche Medizinische Wochenschrift1978;103(43):1695‐700. ">Petersen 1978</a>). With all five studies removed, the results were unaltered (RR 0.59, 95% CI 0.41 to 0.86; heterogeneity: Chi² test = 32.12, df = 5 (P value &lt; 0.0001), I² statistic = 84%). When sequentially removing these studies in order of effect size and then separately in order of study size, the pooled effect estimate ranged from RR 0.66 (95% CI 0.48 to 0.91) to RR 0.54 (95% CI 0.37 to 0.78). </p> <p>During subgroup analyses, we noted the following subgroups to demonstrate significant heterogeneity while the other subgroups in the relevant analysis did not: 'RCTs', 'children' and 'mixed (adult and child participants)', 'estimated 0.027 to 0.037 ml/lb' and 'estimated 0.2 to 0.5 ml/lb', 'exposure up to 8 to 28 days prior to IG' and 'household contact with a diagnosed case'. The subgroups 'mixed (adult and child participants)', 'estimated 0.027 to 0.037 ml/lb' and 'household contact with a diagnosed case' contained only two studies each. We therefore listed each of these studies as seeming to contribute to heterogeneity and thus subject to the sensitivity analysis for the original meta‐analysis. The other subgroups contained more than two studies. In each of these subgroups, we removed each study in turn to assess its impact on the heterogeneity of the subgroup. Where removal of the study resulted in an I² statistic proportion below 60% for the subgroup we listed it as seeming to contribute to heterogeneity and thus subject to the sensitivity analysis for the original meta‐analysis. The studies thus listed for removal during sensitivity analyses were: <a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>; <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>; <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a>; <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a>; and <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a>. We removed studies in each analysis until overall heterogeneity did not meet our protocol specified definition of important heterogeneity (I² statistic &lt; 60% and P value &lt; 0.1). Removing the specified studies in order of the magnitude of the estimate of effect from lowest to highest resulted in removal of <a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>, <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a> and <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a> (heterogeneity: Chi² test = 10.36, df = 7 (P value = 0.17); I² statistic = 32%) and RR 0.36 (95% CI 0.21 to 0.60). Removing these studies in order of the magnitude of the estimate of effect from highest to lowest resulted in removal of <a href="./references#CD010586-bbs2-0002" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953b</a>, <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a> and <a href="./references#CD010586-bbs2-0009" title="McDonaldJC . Gamma‐globulin for prevention of rubella in pregnancy. British Medical Journal1963;2:416‐8. ">McDonald 1963</a> (heterogeneity: Chi² test = 10.50, df = 7 (P value = 0.16); I² statistic = 33%) and RR 0.70 (95% CI 0.46 to 1.04). Removing the studies according to study size from largest to smallest resulted in removal of all five studies identified as seeming to contribute to heterogeneity (heterogeneity: Chi² test = 7.26, df = 5 (P value = 0.20); I² statistic = 31%) and RR 0.43 (95% CI 0.24 to 0.77). Removing the studies according to study size from smallest to largest resulted in removal of <a href="./references#CD010586-bbs2-0001" title="AndersonSG , McLorinanH . Convalescent rubella gamma globulin as a possible prophylactic against rubella. Medical Journal of Australia1953;1:182‐5. ">Anderson 1953a</a>, <a href="./references#CD010586-bbs2-0003" title="DoegeTC , KimKSW . Studies of rubella and its prevention with immune globulin. Journal of the American Medical Association1967;200(7):104‐10. ">Doege 1967</a> and <a href="./references#CD010586-bbs2-0004" title="GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Experimental studies with rubella: evaluation of gamma globulin for prophylaxis. Archiv fur die Gesamte Virusforschung1965;16:513‐6. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies of the natural history and prevention of rubella. American Journal of Diseases of Children1965;110(4):348‐65. GreenRH , BalsamoMR , GilesJP , KrugmanS , MirickGS . Studies on the experimental transmission, clinical course, epidemiology and prevention of rubella. Transactions of the Association of American Physicians1964;77:118‐25. ">Green 1965a</a> (heterogeneity: Chi² test = 10.36, df = 7 (P value = 0.17); I² statistic = 32%) and RR 0.36 (95% CI 0.21 to 0.60). </p> </section> </section> <section id="CD010586-sec-0070"> <h5 class="title">2. Cases of congenital rubella infection</h5> <p>No included study measured the outcome cases of congenital rubella infection.</p> </section> <section id="CD010586-sec-0071"> <h5 class="title">3. Cases of congenital rubella syndrome</h5> <p>One included study reported on cases of congenital rubella syndrome (<a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>). This study did not identify any cases of congenital rubella syndrome among the infants born to the participants in either the 'high' titre (HI titre 512) intervention or the 'low' titre (HI titre 64) control group. The study reported that the rate of stillbirths (one of 83 participants) and spontaneous abortions (five of 83 participants) was within that expected, however the rates among those who were found to be susceptible to rubella prior to gamma‐globulin administration was not reported (total of 41 of the original 83 participants). One of the five participants diagnosed as contracting rubella during their early pregnancy was the participant who suffered a stillbirth. The study did not report whether this participant had been in the high titre or low titre gamma‐globulin group. </p> </section> </section> <section id="CD010586-sec-0072"> <h4 class="title">Secondary outcomes  </h4> <section id="CD010586-sec-0073"> <h5 class="title">1. Occurrence of serious adverse events.</h5> <p>No included studies measured or reported on adverse events.</p> </section> <section id="CD010586-sec-0074"> <h5 class="title">2. Occurrence of non‐serious adverse events.</h5> <p>No included studies measured or reported on adverse events.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010586-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010586-sec-0075"></div> <section id="CD010586-sec-0076"> <h3 class="title" id="CD010586-sec-0076">Summary of main results</h3> <p>We included 12 studies in this review: seven randomised controlled trials (RCTs) and five controlled clinical trials (CCTs) where the means of allocation of participants was not reported. We did not include any unpublished studies. </p> <p>We included 11 studies in meta‐analysis of gamma‐globulin versus control (saline or no treatment) for rubella cases. The result favoured the intervention group (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.45 to 0.83) but was heterogenous (Chi² test = 36.59, df = 10 (P value &lt; 0.0001); I² statistic = 73%). This result was robust to sensitivity analyses. </p> <p>Heterogeneity was not explained by protocol specified subgroup analyses that considered a single factor, but was explained in a post hoc analysis that considered two of these factors simultaneously. We subgrouped studies according to the estimated volume of gamma‐globulin administered per pound of bodyweight and then removed those studies where the intervention was administered more than five days after participant exposure to rubella. The test of subgroup differences demonstrated heterogeneity between subgroups according to our protocol definition and there appeared to be greater effectiveness of the intervention when a greater volume of gamma‐globulin was administered ('0.027 to 0.037 ml/lb' RR 1.6 (95% CI 0.57 to 4.52); '0.1 to 0.15 ml/lb' RR 0.53 (95% CI 0.29 to 0.99); '0.2 to 0.5 ml/lb' RR 0.2 (95% CI 0.04 to 1.00)). </p> <p>No studies measured the outcome congenital rubella infection. One included study reported on congenital rubella syndrome, reporting no cases among participants who were fewer than nine weeks pregnant at enrolment and who were randomised to one of two gamma‐globulin groups ('high' or 'low' rubella titre). However, the study did not report how congenital rubella syndrome was measured and did not report the length of follow‐up according to intervention group. This study did not include a non‐treatment group. </p> <p>No included study measured adverse events.</p> </section> <section id="CD010586-sec-0077"> <h3 class="title" id="CD010586-sec-0077">Overall completeness and applicability of evidence</h3> <p>Pregnant women were not recruited in any of the studies included in meta‐analyses and only one study attempted to assess the effect of post‐exposure passive immunisation for preventing congenital rubella syndrome. The evidence is therefore insufficient to directly conclude the effectiveness of passive immunisation for preventing congenital rubella syndrome. </p> <p>The evidence for preventing rubella cases included participants with a range of ages and both genders. Included studies were undertaken in high‐income countries with predominantly Caucasian populations. The health status of participants apart from their exposure to rubella was not reported but it is likely that most were otherwise healthy individuals. Given this, it seems reasonable to generalise the results to the susceptible, healthy, non‐pregnant population of high‐income countries. While it is likely that rubella could also be prevented by post‐exposure passive immunisation of other susceptible individuals, no conclusions can be drawn about possible differences in the magnitude of effect. </p> <p>None of the included studies measured adverse events associated with passive immunisation. Other literature must be examined in this respect. </p> </section> <section id="CD010586-sec-0078"> <h3 class="title" id="CD010586-sec-0078">Quality of the evidence</h3> <p>We rated no included studies at a low risk of bias for all criteria. Critical appraisal was constrained by a lack of information in most studies, yet study authors could not be contacted to supplement the information reported because of the age of the studies. Despite these limitations, we have rated the quality of the evidence as moderate based on the initial meta‐analysis (see <a href="./full#CD010586-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Subgrouping according to study type to account for those included studies where allocation of participants was not specified as random demonstrated that the subgroup of CCTs had an estimate of effect closer to the null than the subgroup of RCTs. Thus if these studies were not randomised trials, their inclusion has biased the overall effect estimate towards, rather than away from the null. </p> <p>Subgrouping according to funder to examine those studies with potential conflicts of interest demonstrated that the subgroup where gamma‐globulin was provided by a company had an estimate of effect closer to the null than the subgroup with no known potential conflicts of interest. While three studies included in those without known conflict of interest did not report funder information, excluding these studies reduced, but did not reverse the direction of the difference between the subgroups. Thus, the inclusion of studies with known potential conflicts of interest may underestimate rather than overestimate the effect size. </p> <p>Sensitivity analyses also supported the overall beneficial result. The overall effect estimate was either unaltered or larger when we removed studies with a higher risk of bias. Removing studies seeming to contribute to heterogeneity in various sequences did not reverse the direction of effect and in three of the four analyses the estimate of effect increased rather than decreased. </p> <p>Acknowledging that volume of gamma‐globulin per pound of bodyweight was approximated for some studies, we observed an apparent dose effect when the time between exposure and intervention was simultaneously accounted for, increasing confidence in the results. </p> </section> <section id="CD010586-sec-0079"> <h3 class="title" id="CD010586-sec-0079">Potential biases in the review process</h3> <p>We used a filter for study design to reduce the results of the electronic searches to a manageable number. However, the use of the filter may have excluded relevant studies. </p> <p>We were unable to contact the study authors of the retrieved studies, therefore we necessarily relied on reported information. We therefore may have excluded relevant studies because of the lack of information reported. Similarly, we may have over‐ or underestimated the potential bias in included studies. </p> <p>Including studies that did not specify that they used a randomised process for allocating participants to subgroups may be seen as a bias in the review process. However, subgroup analysis and sensitivity analysis both reinforced that the studies included in the meta‐analysis in that way reduced rather than increased the estimate of effect. </p> <p>We specified the subgroup analyses to be conducted in our protocol, but were unable to define the specific subgroups for some of these: dose of immunoglobulins; dose of rubella‐specific immunoglobulins; timing of administration of intervention in relation to exposure. This was because categories with clinical relevance had not been defined by the scientific or clinical communities. We therefore defined these categories based on the included studies. </p> <p>When subgrouping studies by volume of immunoglobulin administered, we used standard weights for adults and adolescents to estimate the volume administered per pound of bodyweight where participant weights were not given. While this would have resulted in imprecision, it was unlikely to have resulted in misclassification between subgroups given there was a considerable degree of separation between the range of volumes defining each subgroup. </p> <p>We undertook <a href="./references#CD010586-fig-0012" title="">Analysis 1.9</a>, which combined dose of immunoglobulin subgroups with time between exposure and intervention, post hoc based on immunological and clinical principles. This brought the number of subgroup analyses to eight, which may be felt to possibly result in false negative or false positive significance tests. However, the results of <a href="./references#CD010586-fig-0012" title="">Analysis 1.9</a> are supported by the indirect evidence of the impact of dose and timing of the intervention in relation to post‐exposure passive immunisation for preventing both measles (<a href="./references#CD010586-bbs2-0178" title="RamsayM , ManikkavasaganG , BrownK , CraigL . Post exposure prophylaxis for measles: revised guidance May 2009. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/322634/Post_exposure_prophylaxis_for_measles.pdf 2009 (accessed 29 April 2015). ">Ramsay 2009</a>) and hepatitis A (<a href="./references#CD010586-bbs2-0189" title="Thomas L and the Hepatitis A Guidelines Group. Guidance for the Prevention and Control of Hepatitis A Infection. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/363023/Guidance_for_the_Prevention_and_Control_of_Hepatitis_A_Infection.pdf 2009 (accessed 23 March 2015). ">Thomas 2009</a>); the magnitude of the difference in the estimates of effect between subgroups within <a href="./references#CD010586-fig-0012" title="">Analysis 1.9</a>; and that this between‐study relationship is replicated (although not statistically significantly) within <a href="./references#CD010586-bbs2-0008" title="McCallinPF , TraubRG , SeverJL , GilkesonMR , FuccilloDA , LeyAC . Gammaglobulin as prophylaxis against rubella‐induced congenital anomalies. Obstetrics and Gynaecology1972;39(2):185‐9. ">McCallin 1972</a>, which was not included in this meta‐analysis. </p> </section> <section id="CD010586-sec-0080"> <h3 class="title" id="CD010586-sec-0080">Agreements and disagreements with other studies or reviews</h3> <p>No previous systematic review has examined passive immunisation for the prevention of rubella or congenital rubella syndrome. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010586-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010586-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010586-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010586-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 1 Rubella cases." data-id="CD010586-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 1 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 2 Rubella cases." data-id="CD010586-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 2 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 3 Rubella cases." data-id="CD010586-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 3 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 4 Rubella cases." data-id="CD010586-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 4 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 5 Rubella cases." data-id="CD010586-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 5 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 6 Rubella cases." data-id="CD010586-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 6 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 7 Rubella cases." data-id="CD010586-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 7 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 8 Rubella cases." data-id="CD010586-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 8 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010586-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/urn:x-wiley:14651858:media:CD010586:CD010586-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_t/tCD010586-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 9 Rubella cases." data-id="CD010586-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Gamma‐globulin versus control (no treatment or saline), Outcome 9 Rubella cases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/media/CDSR/CD010586/image_n/nCD010586-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010586-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> susceptible people exposed to rubella<br/> <b>Settings:</b> community, different residential institutions, universities and medical settings<br/> <b>Intervention:</b> gamma‐globulin<br/> <b>Comparison:</b> saline or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control (saline or no treatment)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Gamma‐globulin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rubella cases</b> <br/> Initial meta‐analysis ‐ clinical diagnosis or serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 3 to 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.45 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>166 per 1000</b> <br/> (123 to 226) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (257 to 474) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.027 to 0.037 ml/lb<sup>11</sup> </b> <br/> Clinical diagnosis by 2 physicians<br/> Follow‐up: 21+ days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.6</b> <br/> (0.57 to 4.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>533 per 1000</b> <br/> (190 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>914 per 1000</b> <br/> (325 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.1 to 0.15 ml/lb<sup>11</sup> </b> <br/> Serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 6 to 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.53</b> <br/> (0.29 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>37<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>765 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>405 per 1000</b> <br/> (222 to 757) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b> <br/> (166 to 565) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Subgroup: rubella cases Estimated dose 0.2 to 0.5 ml/lb<sup>11</sup> </b> <br/> Serology +/‐ virus isolation +/‐ clinical signs<br/> Follow‐up: 3 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.2</b> <br/> (0.04 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>28<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,8,9,10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (13 to 333) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>571 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> <br/> (23 to 571) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of congenital rubella infection</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured the outcome congenital rubella infection</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases of congenital rubella syndrome</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies of gamma‐globulin versus control measured the outcome congenital rubella syndrome<sup>12</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No included studies measured adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies included in the initial meta‐analysis. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for risk of bias. Most information was from studies at low and unclear risk of bias. Two studies were at high risk of detection bias only. Three studies were at high risk of selective reporting only, and this was unlikely to affect their results.<br/> <sup>2</sup>Downgraded one level for inconsistency. The studies' results were statistically heterogenous.<br/> <sup>3</sup>Upgraded one level for plausible confounding would reduce the measure of effect. The plausible confounding factors we listed a priori were: dose, time between exposure and intervention, immunosuppression, age and gestation. No studies in this meta‐analysis included pregnant women or identified immunosuppressed individuals. Subgroup analysis by age showed no difference between the subgroups. This analysis includes studies where the intervention was administered longer than five days after exposure and includes studies that administered lower volumes of immunoglobulin per unit weight than others. Both of these factors would reduce the measure of effect.<br/> <sup>4</sup>Downgraded one level for risk of bias. The sole study in this subgroup was at high risk of detection bias as the outcome was assessed subjectively and there was no reported blinding of outcome assessors.<br/> <sup>5</sup>Downgraded two levels for imprecision. The sole study in this subgroup had a small sample size and the resulting confidence interval is wide.<br/> <sup>6</sup>Upgraded one level for apparent dose response effect. While there is overlap in the confidence intervals, there appeared to be heterogeneity across estimated dose subgroups (P value = 0.07; I² = 62.4%) and the estimates of effect seemed to indicate greater effectiveness with greater estimated dose.<br/> <sup>7</sup>Downgraded one level for imprecision. Each trial in this subgroup was of small sample size and the overall sample size for the subgroup is small. However, the confidence interval does not include one.<br/> <sup>8</sup>Downgraded one level for risk of bias. Two of the three studies in this subgroup had a high risk of selective reporting bias.<br/> <sup>9</sup>Downgraded two levels for imprecision. The trials in this subgroup were small, the overall sample size of the subgroup was small and the confidence interval of the pooled estimate of effect extended to 1.00.<br/> <sup>10</sup>Upgraded one level for large effect estimate. The pooled estimate of effect for this subgroup was 0.2.<br/> <sup>11</sup>This subgroup analysis excluded studies where the intervention was provided more than five days after exposure.<br/> <sup>12</sup>One study included in the review compared a 'high' titre gamma‐globulin with a 'low' titre gamma‐globulin control group. This study did not identify any cases of congenital rubella syndrome among any of the infants born to participants although the means of assessment was not reported and the length of follow‐up was not given by study group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gamma‐globulin compared to control (saline or no treatment) for preventing rubella or congenital rubella syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/full#CD010586-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010586-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gamma‐globulin versus control (no treatment or saline)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Controlled clinical trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.38, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adult participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Child participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.24, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Mixed (adult and child participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Estimated 0.027 to 0.037 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.36, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Estimated 0.1 to 0.15 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.44, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Estimated 0.2 to 0.5 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.53, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Exposure 24 hours to 5 days prior to IG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Exposure up to 8 to 28 days prior to IG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.56, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Artificial exposure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Controlled exposure to infected person</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.42, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Household contact with diagnosed case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Cases defined on clinical grounds</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.36, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Laboratory‐confirmed cases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.50, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 No known conflict of interest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.29, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Potential conflict of interest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.57, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Rubella cases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Estimated 0.027 to 0.037 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.57, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Estimated 0.1 to 0.15 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.29, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Estimated 0.2 to 0.5 ml/lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.04, 1.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Gamma‐globulin versus control (no treatment or saline)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010586.pub2/references#CD010586-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010586.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010586-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010586-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010586-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010586-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ta#CD010586-note-0003">தமிழ்</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010586\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010586\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010586\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010586\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010586\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010586.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010586.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010586.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010586.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010586.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725585570"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010586.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725585574"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010586.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7ed65efaf466',t:'MTc0MDcyNTU4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 